{
  "file_name": "CUAD_v1/full_contract_pdf\\Part_I\\Development\\IbioInc_20200313_8-K_EX-10.1_12052678_EX-10.1_Development Agreement.pdf",
  "annotations": [
    {
      "id": "IbioInc_20200313_8-K_EX-10.1_12052678_EX-10.1_Development Agreement__Document Name_0",
      "question": "Highlight the parts (if any) of this contract related to \"Document Name\" that should be reviewed by a lawyer. Details: The name of the contract",
      "answer_text": "MASTER JOINT DEVELOPMENT AGREEMENT",
      "page_number": 0,
      "words": [
        {
          "text": "MASTER JOINT DEVELOPMENT AGREEMENT",
          "bbox": [
            1182.0,
            455.0,
            2121.0,
            492.0
          ],
          "confidence": 0.9990029335021973
        }
      ],
      "nearby_headers": [
        {
          "text": "MASTER JOINT DEVELOPMENT AGREEMENT",
          "page": 0,
          "bbox": [
            1182.0,
            455.0,
            2121.0,
            492.0
          ]
        }
      ]
    },
    {
      "id": "IbioInc_20200313_8-K_EX-10.1_12052678_EX-10.1_Development Agreement__Parties_0",
      "question": "Highlight the parts (if any) of this contract related to \"Parties\" that should be reviewed by a lawyer. Details: The two or more parties who signed the contract",
      "answer_text": "iBio Inc.",
      "page_number": 0,
      "words": [
        {
          "text": "This Master Joint Development Agreement (\"Agreement\") is between iBio Inc., a Public corporation, with a location at iBio Inc., 600 Madison Ave,",
          "bbox": [
            275.0,
            504.0,
            3027.0,
            556.0
          ],
          "confidence": 0.9988492131233215
        }
      ],
      "nearby_headers": [
        {
          "text": "MASTER JOINT DEVELOPMENT AGREEMENT",
          "page": 0,
          "bbox": [
            1182.0,
            455.0,
            2121.0,
            492.0
          ]
        }
      ]
    },
    {
      "id": "IbioInc_20200313_8-K_EX-10.1_12052678_EX-10.1_Development Agreement__Parties_0",
      "question": "Highlight the parts (if any) of this contract related to \"Parties\" that should be reviewed by a lawyer. Details: The two or more parties who signed the contract",
      "answer_text": "Beijing CC-Pharming Ltd.",
      "page_number": 0,
      "words": [
        {
          "text": "Suite O1601 NY, NY 10022-1735 and Beijing CC-Pharming Ltd. of Beijing, China (\"CC-Pharming\"), a Chinese Corporation with a location at Shunyi",
          "bbox": [
            279.0,
            566.0,
            3027.0,
            609.0
          ],
          "confidence": 0.9916648864746094
        }
      ],
      "nearby_headers": [
        {
          "text": "MASTER JOINT DEVELOPMENT AGREEMENT",
          "page": 0,
          "bbox": [
            1182.0,
            455.0,
            2121.0,
            492.0
          ]
        }
      ]
    },
    {
      "id": "IbioInc_20200313_8-K_EX-10.1_12052678_EX-10.1_Development Agreement__Parties_0",
      "question": "Highlight the parts (if any) of this contract related to \"Parties\" that should be reviewed by a lawyer. Details: The two or more parties who signed the contract",
      "answer_text": "CC-Pharming",
      "page_number": 0,
      "words": [
        {
          "text": "Suite O1601 NY, NY 10022-1735 and Beijing CC-Pharming Ltd. of Beijing, China (\"CC-Pharming\"), a Chinese Corporation with a location at Shunyi",
          "bbox": [
            279.0,
            566.0,
            3027.0,
            609.0
          ],
          "confidence": 0.9916648864746094
        }
      ],
      "nearby_headers": [
        {
          "text": "MASTER JOINT DEVELOPMENT AGREEMENT",
          "page": 0,
          "bbox": [
            1182.0,
            455.0,
            2121.0,
            492.0
          ]
        }
      ]
    },
    {
      "id": "IbioInc_20200313_8-K_EX-10.1_12052678_EX-10.1_Development Agreement__Agreement Date_10",
      "question": "Highlight the parts (if any) of this contract related to \"Agreement Date\" that should be reviewed by a lawyer. Details: The date of the contract",
      "answer_text": "August 08, 2018",
      "page_number": 10,
      "words": [
        {
          "text": "Date: August 08, 2018",
          "bbox": [
            1657.0,
            572.0,
            2064.0,
            610.0
          ],
          "confidence": 0.9966025352478027
        }
      ]
    },
    {
      "id": "IbioInc_20200313_8-K_EX-10.1_12052678_EX-10.1_Development Agreement__Effective Date_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Effective Date\" that should be reviewed by a lawyer. Details: The date when the contract is effective ",
      "answer_text": "The term of this Agreement (\"Term\") will begin on the date this Agreement is signed by the last signatory (\"Effective Date\") and remain in effect for [***]; provided, however, that the terms of this Agreement shall remain applicable to any SOW that was executed by the Parties prior to the expiration or termination of this Agreement but whose period of performance extends beyond the expiration or termination of this Agreement.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.1",
          "bbox": [
            2800.0,
            283.0,
            3025.0,
            322.0
          ],
          "confidence": 0.9997009634971619
        },
        {
          "text": "NOTE: Certain information indicated with [***] in this document has been omitted from this exhibit because it is both (i) not material and (ii).",
          "bbox": [
            275.0,
            338.0,
            3027.0,
            384.0
          ],
          "confidence": 0.9894452691078186
        },
        {
          "text": "would be competitively harmful if publicly disclosed.",
          "bbox": [
            281.0,
            397.0,
            1258.0,
            440.0
          ],
          "confidence": 0.9874401688575745
        },
        {
          "text": "MASTER JOINT DEVELOPMENT AGREEMENT",
          "bbox": [
            1182.0,
            455.0,
            2121.0,
            492.0
          ],
          "confidence": 0.9990029335021973
        },
        {
          "text": "This Master Joint Development Agreement (\"Agreement\") is between iBio Inc., a Public corporation, with a location at iBio Inc., 600 Madison Ave,",
          "bbox": [
            275.0,
            504.0,
            3027.0,
            556.0
          ],
          "confidence": 0.9988492131233215
        },
        {
          "text": "Suite O1601 NY, NY 10022-1735 and Beijing CC-Pharming Ltd. of Beijing, China (\"CC-Pharming\"), a Chinese Corporation with a location at Shunyi",
          "bbox": [
            279.0,
            566.0,
            3027.0,
            609.0
          ],
          "confidence": 0.9916648864746094
        },
        {
          "text": "District, Beijing, China, 101312, each of the foregoing being individually referred to as a \"Party\" and collectively as the \"Parties\".",
          "bbox": [
            275.0,
            619.0,
            2664.0,
            665.0
          ],
          "confidence": 0.9942342042922974
        },
        {
          "text": "WHEREAS, iBio and CC-Pharming wish to establish a long-term working relationship for various joint research and development projects",
          "bbox": [
            444.0,
            676.0,
            3027.0,
            724.0
          ],
          "confidence": 0.9975687861442566
        },
        {
          "text": "(\"Projects) related to the development of various products, with the work for each Project to be described in a separate Statement of Work.",
          "bbox": [
            279.0,
            735.0,
            3029.0,
            777.0
          ],
          "confidence": 0.9938633441925049
        },
        {
          "text": "(\"SOw\") agreed by the Parties;",
          "bbox": [
            281.0,
            789.0,
            868.0,
            835.0
          ],
          "confidence": 0.9870513081550598
        },
        {
          "text": "WHEREAS, iBio has developed and owns proprietary technology used to produce proteins using proprietary vector systems that support",
          "bbox": [
            444.0,
            844.0,
            3029.0,
            892.0
          ],
          "confidence": 0.9940124750137329
        },
        {
          "text": "transient gene expression and protein production in plants, and iBio has developed and/or acquired additional proprietary biopharmaceutical",
          "bbox": [
            275.0,
            901.0,
            3031.0,
            947.0
          ],
          "confidence": 0.991813063621521
        },
        {
          "text": "technology, cGMP manufacturing expertise (\"iBio's Technology\"), and a facility design team that provides capabilities for application to the",
          "bbox": [
            279.0,
            963.0,
            3025.0,
            1000.0
          ],
          "confidence": 0.9882965087890625
        },
        {
          "text": "development of biotherapeutics; and.",
          "bbox": [
            279.0,
            1016.0,
            972.0,
            1058.0
          ],
          "confidence": 0.9877834320068359
        },
        {
          "text": "WHEREAs, iBio and CC-Pharming, wish to develop one or more biopharmaceuticals Product(s) (each a \"Product\") based on iBio's",
          "bbox": [
            446.0,
            1071.0,
            3029.0,
            1113.0
          ],
          "confidence": 0.987923264503479
        },
        {
          "text": "proprietary and patented plant-based protein production technology and know-how;.",
          "bbox": [
            275.0,
            1127.0,
            1861.0,
            1173.0
          ],
          "confidence": 0.9903185963630676
        },
        {
          "text": "WHEREAs, iBio and CC-Pharming wish to develop a long-term, mutually beneficial relationship for the production and sale of",
          "bbox": [
            448.0,
            1184.0,
            3030.0,
            1228.0
          ],
          "confidence": 0.9862040281295776
        },
        {
          "text": "biopharmaceuticals in China and to form a collaborative business venture to be majority owned and controlled by CC-Pharming and minority owned",
          "bbox": [
            277.0,
            1237.0,
            3029.0,
            1283.0
          ],
          "confidence": 0.9991291761398315
        },
        {
          "text": "by iBio; and",
          "bbox": [
            279.0,
            1296.0,
            508.0,
            1339.0
          ],
          "confidence": 0.9808014035224915
        },
        {
          "text": "NOw, THEREFORE, for good and valuable consideration as stated herein, the sufficiency of which is hereby expressly acknowledged by",
          "bbox": [
            442.0,
            1349.0,
            3023.0,
            1396.0
          ],
          "confidence": 0.99495530128479
        },
        {
          "text": "each Party, iBio and CC-Pharming agree as follows:",
          "bbox": [
            279.0,
            1409.0,
            1223.0,
            1451.0
          ],
          "confidence": 0.999891996383667
        },
        {
          "text": "1.0",
          "bbox": [
            274.0,
            1460.0,
            344.0,
            1508.0
          ],
          "confidence": 0.9981430172920227
        },
        {
          "text": "Limited Technology License",
          "bbox": [
            446.0,
            1464.0,
            982.0,
            1504.0
          ],
          "confidence": 0.9944542646408081
        },
        {
          "text": "1.1",
          "bbox": [
            274.0,
            1517.0,
            341.0,
            1561.0
          ],
          "confidence": 0.9970695972442627
        },
        {
          "text": "iBio hereby grants to CC-Pharming for the term of this Agreement, a nonexclusive, non- assignable, non-sublicensable, limited right and",
          "bbox": [
            448.0,
            1520.0,
            3021.0,
            1562.0
          ],
          "confidence": 0.996475875377655
        },
        {
          "text": "production of Product(s) and work to be performed under this Agreement. Each Product will be set forth in a separate Statement of Work",
          "bbox": [
            446.0,
            1630.0,
            3021.0,
            1676.0
          ],
          "confidence": 0.9869741201400757
        },
        {
          "text": "in the form set forth in Appendix A, which will be signed by representatives of each Party with signing authority. Each phase of the",
          "bbox": [
            446.0,
            1690.0,
            3020.0,
            1732.0
          ],
          "confidence": 0.9884188175201416
        },
        {
          "text": "project(s) will be subject to the terms and conditions set forth in this Agreement unless otherwise provided for or in a Statement of Work.",
          "bbox": [
            442.0,
            1738.0,
            3023.0,
            1793.0
          ],
          "confidence": 0.9936604499816895
        },
        {
          "text": "(\"SOw'), including but not limited to project purpose, project phases, and a project budget..",
          "bbox": [
            446.0,
            1800.0,
            2159.0,
            1846.0
          ],
          "confidence": 0.9933698773384094
        },
        {
          "text": "Master Joint Development Agreement iBio CC-Pharming",
          "bbox": [
            279.0,
            1910.0,
            1334.0,
            1957.0
          ],
          "confidence": 0.9935949444770813
        },
        {
          "text": "Page 1 of 12",
          "bbox": [
            2800.0,
            1911.0,
            3029.0,
            1955.0
          ],
          "confidence": 0.9980977177619934
        },
        {
          "text": "Source: IBIO, INC., 8-K, 3/13/2020",
          "bbox": [
            333.0,
            4435.0,
            1022.0,
            4479.0
          ],
          "confidence": 0.990613579750061
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "MASTER JOINT DEVELOPMENT AGREEMENT",
          "page": 0,
          "bbox": [
            1182.0,
            455.0,
            2121.0,
            492.0
          ]
        }
      ]
    },
    {
      "id": "IbioInc_20200313_8-K_EX-10.1_12052678_EX-10.1_Development Agreement__Effective Date_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Effective Date\" that should be reviewed by a lawyer. Details: The date when the contract is effective ",
      "answer_text": "The term of this Agreement (\"Term\") will begin on the date this Agreement is signed by the last signatory (\"Effective Date\") and remain in effect for [***]; provided, however, that the terms of this Agreement shall remain applicable to any SOW that was executed by the Parties prior to the expiration or termination of this Agreement but whose period of performance extends beyond the expiration or termination of this Agreement.",
      "page_number": 1,
      "words": [
        {
          "text": "1.2",
          "bbox": [
            274.0,
            283.0,
            343.0,
            327.0
          ],
          "confidence": 0.999828040599823
        },
        {
          "text": "No right or license is being conveyed to CC-Pharming to export Products or to otherwise use the Technology in any country other than",
          "bbox": [
            444.0,
            283.0,
            3020.0,
            327.0
          ],
          "confidence": 0.9960402250289917
        },
        {
          "text": "China.",
          "bbox": [
            444.0,
            338.0,
            564.0,
            382.0
          ],
          "confidence": 0.9998229146003723
        },
        {
          "text": "1.3",
          "bbox": [
            274.0,
            395.0,
            343.0,
            439.0
          ],
          "confidence": 0.9999030232429504
        },
        {
          "text": "iBio will work with CC-Pharming to perform a thorough Manufacturing Development Program based from an initial comprehensive two-",
          "bbox": [
            444.0,
            395.0,
            3020.0,
            440.0
          ],
          "confidence": 0.991921067237854
        },
        {
          "text": "day charrette to be held at its subsidiary iBio CDMO LLC facility in Bryan, Texas with the goals of CC-Pharming understanding the",
          "bbox": [
            446.0,
            451.0,
            3020.0,
            497.0
          ],
          "confidence": 0.9884581565856934
        },
        {
          "text": "definitive capital expenditure necessary and initiating a preliminary design for the first Product. iBio will provide an architect, construction",
          "bbox": [
            448.0,
            510.0,
            3021.0,
            554.0
          ],
          "confidence": 0.9959992170333862
        },
        {
          "text": "supervisor, mechanical engineer and process engineer with knowledge of the iBio CDMO facility currently in operation in Bryan, Texas.",
          "bbox": [
            448.0,
            566.0,
            2960.0,
            609.0
          ],
          "confidence": 0.9869726896286011
        },
        {
          "text": "1.4",
          "bbox": [
            274.0,
            619.0,
            343.0,
            663.0
          ],
          "confidence": 0.9999340176582336
        },
        {
          "text": "CC-Pharming hereby expressly acknowledges the validity and highly confidential and proprietary nature of iBio's Technology and",
          "bbox": [
            446.0,
            619.0,
            3021.0,
            665.0
          ],
          "confidence": 0.993236243724823
        },
        {
          "text": "technical information, know-how, documents, materials, software, vectors, constructs, trade secrets, and other valuable business or",
          "bbox": [
            446.0,
            676.0,
            3020.0,
            720.0
          ],
          "confidence": 0.9944519996643066
        },
        {
          "text": "scientific information that iBio will share with CC-Pharming in order to fulfill the purpose of this Agreement, namely, to form a legal",
          "bbox": [
            444.0,
            731.0,
            3021.0,
            777.0
          ],
          "confidence": 0.9856650829315186
        },
        {
          "text": "structure for a collaborative business venture in which CC-Pharming and iBio shall share revenue from product sales. iBio's double-digit",
          "bbox": [
            446.0,
            791.0,
            3021.0,
            833.0
          ],
          "confidence": 0.994662344455719
        },
        {
          "text": "percentage, minority interest in this structure will provide compensation to iBio for providing CC-Pharming with a license to use iBio's.",
          "bbox": [
            444.0,
            844.0,
            3021.0,
            892.0
          ],
          "confidence": 0.9963811039924622
        },
        {
          "text": "Technology and enabling know-how and will provide CC-Pharming with ongoing and mutually agreed technology transfer services",
          "bbox": [
            446.0,
            903.0,
            3021.0,
            945.0
          ],
          "confidence": 0.9966488480567932
        },
        {
          "text": "relevant to the evolving business and Product(s) of the collaborative venture.",
          "bbox": [
            446.0,
            963.0,
            1898.0,
            1000.0
          ],
          "confidence": 0.9989203214645386
        },
        {
          "text": "1.5",
          "bbox": [
            274.0,
            1011.0,
            344.0,
            1058.0
          ],
          "confidence": 0.9999009966850281
        },
        {
          "text": "The parties agree that the first product focus of the joint business collaboration will be a bio-better or bio-similar version of the",
          "bbox": [
            444.0,
            1012.0,
            3020.0,
            1058.0
          ],
          "confidence": 0.996626079082489
        },
        {
          "text": "therapeutic monoclonal antibody, rituximab. iBio will provide all necessary gene expression and vector technology for the transient.",
          "bbox": [
            446.0,
            1073.0,
            3023.0,
            1117.0
          ],
          "confidence": 0.9934687614440918
        },
        {
          "text": "expression and cGMP manufacturing of this protein in plants and will also provide pilot plant design services, construction consulting,",
          "bbox": [
            442.0,
            1124.0,
            3020.0,
            1175.0
          ],
          "confidence": 0.9993672966957092
        },
        {
          "text": "product and process development services, training, quality management system design, and clinical planning and regulatory consulting.",
          "bbox": [
            448.0,
            1186.0,
            3016.0,
            1228.0
          ],
          "confidence": 0.9921608567237854
        },
        {
          "text": "The tasks to be conducted in the first stage of the joint business collaboration will apply specifically to the rituximab product candidate",
          "bbox": [
            442.0,
            1235.0,
            3021.0,
            1286.0
          ],
          "confidence": 0.9976635575294495
        },
        {
          "text": "but will be applicable, in part, to additional products to be selected by mutual agreement for development, with the timeline for such work",
          "bbox": [
            448.0,
            1296.0,
            3021.0,
            1338.0
          ],
          "confidence": 0.9955782294273376
        },
        {
          "text": "to be determined by CC-Pharming.",
          "bbox": [
            444.0,
            1347.0,
            1082.0,
            1398.0
          ],
          "confidence": 0.9862340688705444
        },
        {
          "text": "1.5",
          "bbox": [
            274.0,
            1405.0,
            343.0,
            1449.0
          ],
          "confidence": 0.8620595335960388
        },
        {
          "text": "Any milestones or completion dates set forth in a Statement of Work will be estimates only, and are not binding on the Parties.",
          "bbox": [
            446.0,
            1405.0,
            2789.0,
            1451.0
          ],
          "confidence": 0.995090901851654
        },
        {
          "text": "2.0",
          "bbox": [
            270.0,
            1458.0,
            344.0,
            1508.0
          ],
          "confidence": 0.9997313022613525
        },
        {
          "text": "Coordinators and Governance Terms",
          "bbox": [
            450.0,
            1466.0,
            1144.0,
            1502.0
          ],
          "confidence": 0.9927111268043518
        },
        {
          "text": "2.1",
          "bbox": [
            272.0,
            1517.0,
            343.0,
            1561.0
          ],
          "confidence": 0.998992919921875
        },
        {
          "text": "Project Technical Coordinators will be appointed by each the Parties for each Statement of Work. The Project Technical Coordinators will",
          "bbox": [
            444.0,
            1517.0,
            3020.0,
            1562.0
          ],
          "confidence": 0.9955620765686035
        },
        {
          "text": "be responsible for exchanging information with the other Party, coordinating any visits and arranging all other matters pertinent to that",
          "bbox": [
            446.0,
            1577.0,
            3021.0,
            1619.0
          ],
          "confidence": 0.9937794208526611
        },
        {
          "text": "Statement of Work.",
          "bbox": [
            448.0,
            1634.0,
            803.0,
            1672.0
          ],
          "confidence": 0.9995152354240417
        },
        {
          "text": "Master Joint Development Agreement iBio CC-Pharming",
          "bbox": [
            279.0,
            1741.0,
            1332.0,
            1789.0
          ],
          "confidence": 0.9914409518241882
        },
        {
          "text": "Page 2 of 12",
          "bbox": [
            2800.0,
            1743.0,
            3029.0,
            1787.0
          ],
          "confidence": 0.9996117949485779
        },
        {
          "text": "Source: IBIO, INC., 8-K, 3/13/2020",
          "bbox": [
            335.0,
            4440.0,
            1022.0,
            4477.0
          ],
          "confidence": 0.997024416923523
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "IbioInc_20200313_8-K_EX-10.1_12052678_EX-10.1_Development Agreement__Effective Date_10",
      "question": "Highlight the parts (if any) of this contract related to \"Effective Date\" that should be reviewed by a lawyer. Details: The date when the contract is effective ",
      "answer_text": "August 08, 2018",
      "page_number": 10,
      "words": [
        {
          "text": "Date: August 08, 2018",
          "bbox": [
            1657.0,
            572.0,
            2064.0,
            610.0
          ],
          "confidence": 0.9966025352478027
        }
      ]
    },
    {
      "id": "IbioInc_20200313_8-K_EX-10.1_12052678_EX-10.1_Development Agreement__Expiration Date_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Expiration Date\" that should be reviewed by a lawyer. Details: On what date will the contract's initial term expire?",
      "answer_text": "The term of this Agreement (\"Term\") will begin on the date this Agreement is signed by the last signatory (\"Effective Date\") and remain in effect for [***]; provided, however, that the terms of this Agreement shall remain applicable to any SOW that was executed by the Parties prior to the expiration or termination of this Agreement but whose period of performance extends beyond the expiration or termination of this Agreement.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.1",
          "bbox": [
            2800.0,
            283.0,
            3025.0,
            322.0
          ],
          "confidence": 0.9997009634971619
        },
        {
          "text": "NOTE: Certain information indicated with [***] in this document has been omitted from this exhibit because it is both (i) not material and (ii).",
          "bbox": [
            275.0,
            338.0,
            3027.0,
            384.0
          ],
          "confidence": 0.9894452691078186
        },
        {
          "text": "would be competitively harmful if publicly disclosed.",
          "bbox": [
            281.0,
            397.0,
            1258.0,
            440.0
          ],
          "confidence": 0.9874401688575745
        },
        {
          "text": "MASTER JOINT DEVELOPMENT AGREEMENT",
          "bbox": [
            1182.0,
            455.0,
            2121.0,
            492.0
          ],
          "confidence": 0.9990029335021973
        },
        {
          "text": "This Master Joint Development Agreement (\"Agreement\") is between iBio Inc., a Public corporation, with a location at iBio Inc., 600 Madison Ave,",
          "bbox": [
            275.0,
            504.0,
            3027.0,
            556.0
          ],
          "confidence": 0.9988492131233215
        },
        {
          "text": "Suite O1601 NY, NY 10022-1735 and Beijing CC-Pharming Ltd. of Beijing, China (\"CC-Pharming\"), a Chinese Corporation with a location at Shunyi",
          "bbox": [
            279.0,
            566.0,
            3027.0,
            609.0
          ],
          "confidence": 0.9916648864746094
        },
        {
          "text": "District, Beijing, China, 101312, each of the foregoing being individually referred to as a \"Party\" and collectively as the \"Parties\".",
          "bbox": [
            275.0,
            619.0,
            2664.0,
            665.0
          ],
          "confidence": 0.9942342042922974
        },
        {
          "text": "WHEREAS, iBio and CC-Pharming wish to establish a long-term working relationship for various joint research and development projects",
          "bbox": [
            444.0,
            676.0,
            3027.0,
            724.0
          ],
          "confidence": 0.9975687861442566
        },
        {
          "text": "(\"Projects) related to the development of various products, with the work for each Project to be described in a separate Statement of Work.",
          "bbox": [
            279.0,
            735.0,
            3029.0,
            777.0
          ],
          "confidence": 0.9938633441925049
        },
        {
          "text": "(\"SOw\") agreed by the Parties;",
          "bbox": [
            281.0,
            789.0,
            868.0,
            835.0
          ],
          "confidence": 0.9870513081550598
        },
        {
          "text": "WHEREAS, iBio has developed and owns proprietary technology used to produce proteins using proprietary vector systems that support",
          "bbox": [
            444.0,
            844.0,
            3029.0,
            892.0
          ],
          "confidence": 0.9940124750137329
        },
        {
          "text": "transient gene expression and protein production in plants, and iBio has developed and/or acquired additional proprietary biopharmaceutical",
          "bbox": [
            275.0,
            901.0,
            3031.0,
            947.0
          ],
          "confidence": 0.991813063621521
        },
        {
          "text": "technology, cGMP manufacturing expertise (\"iBio's Technology\"), and a facility design team that provides capabilities for application to the",
          "bbox": [
            279.0,
            963.0,
            3025.0,
            1000.0
          ],
          "confidence": 0.9882965087890625
        },
        {
          "text": "development of biotherapeutics; and.",
          "bbox": [
            279.0,
            1016.0,
            972.0,
            1058.0
          ],
          "confidence": 0.9877834320068359
        },
        {
          "text": "WHEREAs, iBio and CC-Pharming, wish to develop one or more biopharmaceuticals Product(s) (each a \"Product\") based on iBio's",
          "bbox": [
            446.0,
            1071.0,
            3029.0,
            1113.0
          ],
          "confidence": 0.987923264503479
        },
        {
          "text": "proprietary and patented plant-based protein production technology and know-how;.",
          "bbox": [
            275.0,
            1127.0,
            1861.0,
            1173.0
          ],
          "confidence": 0.9903185963630676
        },
        {
          "text": "WHEREAs, iBio and CC-Pharming wish to develop a long-term, mutually beneficial relationship for the production and sale of",
          "bbox": [
            448.0,
            1184.0,
            3030.0,
            1228.0
          ],
          "confidence": 0.9862040281295776
        },
        {
          "text": "biopharmaceuticals in China and to form a collaborative business venture to be majority owned and controlled by CC-Pharming and minority owned",
          "bbox": [
            277.0,
            1237.0,
            3029.0,
            1283.0
          ],
          "confidence": 0.9991291761398315
        },
        {
          "text": "by iBio; and",
          "bbox": [
            279.0,
            1296.0,
            508.0,
            1339.0
          ],
          "confidence": 0.9808014035224915
        },
        {
          "text": "NOw, THEREFORE, for good and valuable consideration as stated herein, the sufficiency of which is hereby expressly acknowledged by",
          "bbox": [
            442.0,
            1349.0,
            3023.0,
            1396.0
          ],
          "confidence": 0.99495530128479
        },
        {
          "text": "each Party, iBio and CC-Pharming agree as follows:",
          "bbox": [
            279.0,
            1409.0,
            1223.0,
            1451.0
          ],
          "confidence": 0.999891996383667
        },
        {
          "text": "1.0",
          "bbox": [
            274.0,
            1460.0,
            344.0,
            1508.0
          ],
          "confidence": 0.9981430172920227
        },
        {
          "text": "Limited Technology License",
          "bbox": [
            446.0,
            1464.0,
            982.0,
            1504.0
          ],
          "confidence": 0.9944542646408081
        },
        {
          "text": "1.1",
          "bbox": [
            274.0,
            1517.0,
            341.0,
            1561.0
          ],
          "confidence": 0.9970695972442627
        },
        {
          "text": "iBio hereby grants to CC-Pharming for the term of this Agreement, a nonexclusive, non- assignable, non-sublicensable, limited right and",
          "bbox": [
            448.0,
            1520.0,
            3021.0,
            1562.0
          ],
          "confidence": 0.996475875377655
        },
        {
          "text": "production of Product(s) and work to be performed under this Agreement. Each Product will be set forth in a separate Statement of Work",
          "bbox": [
            446.0,
            1630.0,
            3021.0,
            1676.0
          ],
          "confidence": 0.9869741201400757
        },
        {
          "text": "in the form set forth in Appendix A, which will be signed by representatives of each Party with signing authority. Each phase of the",
          "bbox": [
            446.0,
            1690.0,
            3020.0,
            1732.0
          ],
          "confidence": 0.9884188175201416
        },
        {
          "text": "project(s) will be subject to the terms and conditions set forth in this Agreement unless otherwise provided for or in a Statement of Work.",
          "bbox": [
            442.0,
            1738.0,
            3023.0,
            1793.0
          ],
          "confidence": 0.9936604499816895
        },
        {
          "text": "(\"SOw'), including but not limited to project purpose, project phases, and a project budget..",
          "bbox": [
            446.0,
            1800.0,
            2159.0,
            1846.0
          ],
          "confidence": 0.9933698773384094
        },
        {
          "text": "Master Joint Development Agreement iBio CC-Pharming",
          "bbox": [
            279.0,
            1910.0,
            1334.0,
            1957.0
          ],
          "confidence": 0.9935949444770813
        },
        {
          "text": "Page 1 of 12",
          "bbox": [
            2800.0,
            1911.0,
            3029.0,
            1955.0
          ],
          "confidence": 0.9980977177619934
        },
        {
          "text": "Source: IBIO, INC., 8-K, 3/13/2020",
          "bbox": [
            333.0,
            4435.0,
            1022.0,
            4479.0
          ],
          "confidence": 0.990613579750061
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "MASTER JOINT DEVELOPMENT AGREEMENT",
          "page": 0,
          "bbox": [
            1182.0,
            455.0,
            2121.0,
            492.0
          ]
        }
      ]
    },
    {
      "id": "IbioInc_20200313_8-K_EX-10.1_12052678_EX-10.1_Development Agreement__Expiration Date_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Expiration Date\" that should be reviewed by a lawyer. Details: On what date will the contract's initial term expire?",
      "answer_text": "The term of this Agreement (\"Term\") will begin on the date this Agreement is signed by the last signatory (\"Effective Date\") and remain in effect for [***]; provided, however, that the terms of this Agreement shall remain applicable to any SOW that was executed by the Parties prior to the expiration or termination of this Agreement but whose period of performance extends beyond the expiration or termination of this Agreement.",
      "page_number": 1,
      "words": [
        {
          "text": "1.2",
          "bbox": [
            274.0,
            283.0,
            343.0,
            327.0
          ],
          "confidence": 0.999828040599823
        },
        {
          "text": "No right or license is being conveyed to CC-Pharming to export Products or to otherwise use the Technology in any country other than",
          "bbox": [
            444.0,
            283.0,
            3020.0,
            327.0
          ],
          "confidence": 0.9960402250289917
        },
        {
          "text": "China.",
          "bbox": [
            444.0,
            338.0,
            564.0,
            382.0
          ],
          "confidence": 0.9998229146003723
        },
        {
          "text": "1.3",
          "bbox": [
            274.0,
            395.0,
            343.0,
            439.0
          ],
          "confidence": 0.9999030232429504
        },
        {
          "text": "iBio will work with CC-Pharming to perform a thorough Manufacturing Development Program based from an initial comprehensive two-",
          "bbox": [
            444.0,
            395.0,
            3020.0,
            440.0
          ],
          "confidence": 0.991921067237854
        },
        {
          "text": "day charrette to be held at its subsidiary iBio CDMO LLC facility in Bryan, Texas with the goals of CC-Pharming understanding the",
          "bbox": [
            446.0,
            451.0,
            3020.0,
            497.0
          ],
          "confidence": 0.9884581565856934
        },
        {
          "text": "definitive capital expenditure necessary and initiating a preliminary design for the first Product. iBio will provide an architect, construction",
          "bbox": [
            448.0,
            510.0,
            3021.0,
            554.0
          ],
          "confidence": 0.9959992170333862
        },
        {
          "text": "supervisor, mechanical engineer and process engineer with knowledge of the iBio CDMO facility currently in operation in Bryan, Texas.",
          "bbox": [
            448.0,
            566.0,
            2960.0,
            609.0
          ],
          "confidence": 0.9869726896286011
        },
        {
          "text": "1.4",
          "bbox": [
            274.0,
            619.0,
            343.0,
            663.0
          ],
          "confidence": 0.9999340176582336
        },
        {
          "text": "CC-Pharming hereby expressly acknowledges the validity and highly confidential and proprietary nature of iBio's Technology and",
          "bbox": [
            446.0,
            619.0,
            3021.0,
            665.0
          ],
          "confidence": 0.993236243724823
        },
        {
          "text": "technical information, know-how, documents, materials, software, vectors, constructs, trade secrets, and other valuable business or",
          "bbox": [
            446.0,
            676.0,
            3020.0,
            720.0
          ],
          "confidence": 0.9944519996643066
        },
        {
          "text": "scientific information that iBio will share with CC-Pharming in order to fulfill the purpose of this Agreement, namely, to form a legal",
          "bbox": [
            444.0,
            731.0,
            3021.0,
            777.0
          ],
          "confidence": 0.9856650829315186
        },
        {
          "text": "structure for a collaborative business venture in which CC-Pharming and iBio shall share revenue from product sales. iBio's double-digit",
          "bbox": [
            446.0,
            791.0,
            3021.0,
            833.0
          ],
          "confidence": 0.994662344455719
        },
        {
          "text": "percentage, minority interest in this structure will provide compensation to iBio for providing CC-Pharming with a license to use iBio's.",
          "bbox": [
            444.0,
            844.0,
            3021.0,
            892.0
          ],
          "confidence": 0.9963811039924622
        },
        {
          "text": "Technology and enabling know-how and will provide CC-Pharming with ongoing and mutually agreed technology transfer services",
          "bbox": [
            446.0,
            903.0,
            3021.0,
            945.0
          ],
          "confidence": 0.9966488480567932
        },
        {
          "text": "relevant to the evolving business and Product(s) of the collaborative venture.",
          "bbox": [
            446.0,
            963.0,
            1898.0,
            1000.0
          ],
          "confidence": 0.9989203214645386
        },
        {
          "text": "1.5",
          "bbox": [
            274.0,
            1011.0,
            344.0,
            1058.0
          ],
          "confidence": 0.9999009966850281
        },
        {
          "text": "The parties agree that the first product focus of the joint business collaboration will be a bio-better or bio-similar version of the",
          "bbox": [
            444.0,
            1012.0,
            3020.0,
            1058.0
          ],
          "confidence": 0.996626079082489
        },
        {
          "text": "therapeutic monoclonal antibody, rituximab. iBio will provide all necessary gene expression and vector technology for the transient.",
          "bbox": [
            446.0,
            1073.0,
            3023.0,
            1117.0
          ],
          "confidence": 0.9934687614440918
        },
        {
          "text": "expression and cGMP manufacturing of this protein in plants and will also provide pilot plant design services, construction consulting,",
          "bbox": [
            442.0,
            1124.0,
            3020.0,
            1175.0
          ],
          "confidence": 0.9993672966957092
        },
        {
          "text": "product and process development services, training, quality management system design, and clinical planning and regulatory consulting.",
          "bbox": [
            448.0,
            1186.0,
            3016.0,
            1228.0
          ],
          "confidence": 0.9921608567237854
        },
        {
          "text": "The tasks to be conducted in the first stage of the joint business collaboration will apply specifically to the rituximab product candidate",
          "bbox": [
            442.0,
            1235.0,
            3021.0,
            1286.0
          ],
          "confidence": 0.9976635575294495
        },
        {
          "text": "but will be applicable, in part, to additional products to be selected by mutual agreement for development, with the timeline for such work",
          "bbox": [
            448.0,
            1296.0,
            3021.0,
            1338.0
          ],
          "confidence": 0.9955782294273376
        },
        {
          "text": "to be determined by CC-Pharming.",
          "bbox": [
            444.0,
            1347.0,
            1082.0,
            1398.0
          ],
          "confidence": 0.9862340688705444
        },
        {
          "text": "1.5",
          "bbox": [
            274.0,
            1405.0,
            343.0,
            1449.0
          ],
          "confidence": 0.8620595335960388
        },
        {
          "text": "Any milestones or completion dates set forth in a Statement of Work will be estimates only, and are not binding on the Parties.",
          "bbox": [
            446.0,
            1405.0,
            2789.0,
            1451.0
          ],
          "confidence": 0.995090901851654
        },
        {
          "text": "2.0",
          "bbox": [
            270.0,
            1458.0,
            344.0,
            1508.0
          ],
          "confidence": 0.9997313022613525
        },
        {
          "text": "Coordinators and Governance Terms",
          "bbox": [
            450.0,
            1466.0,
            1144.0,
            1502.0
          ],
          "confidence": 0.9927111268043518
        },
        {
          "text": "2.1",
          "bbox": [
            272.0,
            1517.0,
            343.0,
            1561.0
          ],
          "confidence": 0.998992919921875
        },
        {
          "text": "Project Technical Coordinators will be appointed by each the Parties for each Statement of Work. The Project Technical Coordinators will",
          "bbox": [
            444.0,
            1517.0,
            3020.0,
            1562.0
          ],
          "confidence": 0.9955620765686035
        },
        {
          "text": "be responsible for exchanging information with the other Party, coordinating any visits and arranging all other matters pertinent to that",
          "bbox": [
            446.0,
            1577.0,
            3021.0,
            1619.0
          ],
          "confidence": 0.9937794208526611
        },
        {
          "text": "Statement of Work.",
          "bbox": [
            448.0,
            1634.0,
            803.0,
            1672.0
          ],
          "confidence": 0.9995152354240417
        },
        {
          "text": "Master Joint Development Agreement iBio CC-Pharming",
          "bbox": [
            279.0,
            1741.0,
            1332.0,
            1789.0
          ],
          "confidence": 0.9914409518241882
        },
        {
          "text": "Page 2 of 12",
          "bbox": [
            2800.0,
            1743.0,
            3029.0,
            1787.0
          ],
          "confidence": 0.9996117949485779
        },
        {
          "text": "Source: IBIO, INC., 8-K, 3/13/2020",
          "bbox": [
            335.0,
            4440.0,
            1022.0,
            4477.0
          ],
          "confidence": 0.997024416923523
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "IbioInc_20200313_8-K_EX-10.1_12052678_EX-10.1_Development Agreement__Governing Law_1",
      "question": "Highlight the parts (if any) of this contract related to \"Governing Law\" that should be reviewed by a lawyer. Details: Which state/country's law governs the interpretation of the contract?",
      "answer_text": "This Agreement is governed by the laws of the State of Texas, without regard to the conflict of laws provisions thereof.",
      "page_number": 1,
      "words": [
        {
          "text": "1.2",
          "bbox": [
            274.0,
            283.0,
            343.0,
            327.0
          ],
          "confidence": 0.999828040599823
        },
        {
          "text": "No right or license is being conveyed to CC-Pharming to export Products or to otherwise use the Technology in any country other than",
          "bbox": [
            444.0,
            283.0,
            3020.0,
            327.0
          ],
          "confidence": 0.9960402250289917
        },
        {
          "text": "China.",
          "bbox": [
            444.0,
            338.0,
            564.0,
            382.0
          ],
          "confidence": 0.9998229146003723
        },
        {
          "text": "1.3",
          "bbox": [
            274.0,
            395.0,
            343.0,
            439.0
          ],
          "confidence": 0.9999030232429504
        },
        {
          "text": "iBio will work with CC-Pharming to perform a thorough Manufacturing Development Program based from an initial comprehensive two-",
          "bbox": [
            444.0,
            395.0,
            3020.0,
            440.0
          ],
          "confidence": 0.991921067237854
        },
        {
          "text": "day charrette to be held at its subsidiary iBio CDMO LLC facility in Bryan, Texas with the goals of CC-Pharming understanding the",
          "bbox": [
            446.0,
            451.0,
            3020.0,
            497.0
          ],
          "confidence": 0.9884581565856934
        },
        {
          "text": "definitive capital expenditure necessary and initiating a preliminary design for the first Product. iBio will provide an architect, construction",
          "bbox": [
            448.0,
            510.0,
            3021.0,
            554.0
          ],
          "confidence": 0.9959992170333862
        },
        {
          "text": "supervisor, mechanical engineer and process engineer with knowledge of the iBio CDMO facility currently in operation in Bryan, Texas.",
          "bbox": [
            448.0,
            566.0,
            2960.0,
            609.0
          ],
          "confidence": 0.9869726896286011
        },
        {
          "text": "1.4",
          "bbox": [
            274.0,
            619.0,
            343.0,
            663.0
          ],
          "confidence": 0.9999340176582336
        },
        {
          "text": "CC-Pharming hereby expressly acknowledges the validity and highly confidential and proprietary nature of iBio's Technology and",
          "bbox": [
            446.0,
            619.0,
            3021.0,
            665.0
          ],
          "confidence": 0.993236243724823
        },
        {
          "text": "technical information, know-how, documents, materials, software, vectors, constructs, trade secrets, and other valuable business or",
          "bbox": [
            446.0,
            676.0,
            3020.0,
            720.0
          ],
          "confidence": 0.9944519996643066
        },
        {
          "text": "scientific information that iBio will share with CC-Pharming in order to fulfill the purpose of this Agreement, namely, to form a legal",
          "bbox": [
            444.0,
            731.0,
            3021.0,
            777.0
          ],
          "confidence": 0.9856650829315186
        },
        {
          "text": "structure for a collaborative business venture in which CC-Pharming and iBio shall share revenue from product sales. iBio's double-digit",
          "bbox": [
            446.0,
            791.0,
            3021.0,
            833.0
          ],
          "confidence": 0.994662344455719
        },
        {
          "text": "percentage, minority interest in this structure will provide compensation to iBio for providing CC-Pharming with a license to use iBio's.",
          "bbox": [
            444.0,
            844.0,
            3021.0,
            892.0
          ],
          "confidence": 0.9963811039924622
        },
        {
          "text": "Technology and enabling know-how and will provide CC-Pharming with ongoing and mutually agreed technology transfer services",
          "bbox": [
            446.0,
            903.0,
            3021.0,
            945.0
          ],
          "confidence": 0.9966488480567932
        },
        {
          "text": "relevant to the evolving business and Product(s) of the collaborative venture.",
          "bbox": [
            446.0,
            963.0,
            1898.0,
            1000.0
          ],
          "confidence": 0.9989203214645386
        },
        {
          "text": "1.5",
          "bbox": [
            274.0,
            1011.0,
            344.0,
            1058.0
          ],
          "confidence": 0.9999009966850281
        },
        {
          "text": "The parties agree that the first product focus of the joint business collaboration will be a bio-better or bio-similar version of the",
          "bbox": [
            444.0,
            1012.0,
            3020.0,
            1058.0
          ],
          "confidence": 0.996626079082489
        },
        {
          "text": "therapeutic monoclonal antibody, rituximab. iBio will provide all necessary gene expression and vector technology for the transient.",
          "bbox": [
            446.0,
            1073.0,
            3023.0,
            1117.0
          ],
          "confidence": 0.9934687614440918
        },
        {
          "text": "expression and cGMP manufacturing of this protein in plants and will also provide pilot plant design services, construction consulting,",
          "bbox": [
            442.0,
            1124.0,
            3020.0,
            1175.0
          ],
          "confidence": 0.9993672966957092
        },
        {
          "text": "product and process development services, training, quality management system design, and clinical planning and regulatory consulting.",
          "bbox": [
            448.0,
            1186.0,
            3016.0,
            1228.0
          ],
          "confidence": 0.9921608567237854
        },
        {
          "text": "The tasks to be conducted in the first stage of the joint business collaboration will apply specifically to the rituximab product candidate",
          "bbox": [
            442.0,
            1235.0,
            3021.0,
            1286.0
          ],
          "confidence": 0.9976635575294495
        },
        {
          "text": "but will be applicable, in part, to additional products to be selected by mutual agreement for development, with the timeline for such work",
          "bbox": [
            448.0,
            1296.0,
            3021.0,
            1338.0
          ],
          "confidence": 0.9955782294273376
        },
        {
          "text": "to be determined by CC-Pharming.",
          "bbox": [
            444.0,
            1347.0,
            1082.0,
            1398.0
          ],
          "confidence": 0.9862340688705444
        },
        {
          "text": "1.5",
          "bbox": [
            274.0,
            1405.0,
            343.0,
            1449.0
          ],
          "confidence": 0.8620595335960388
        },
        {
          "text": "Any milestones or completion dates set forth in a Statement of Work will be estimates only, and are not binding on the Parties.",
          "bbox": [
            446.0,
            1405.0,
            2789.0,
            1451.0
          ],
          "confidence": 0.995090901851654
        },
        {
          "text": "2.0",
          "bbox": [
            270.0,
            1458.0,
            344.0,
            1508.0
          ],
          "confidence": 0.9997313022613525
        },
        {
          "text": "Coordinators and Governance Terms",
          "bbox": [
            450.0,
            1466.0,
            1144.0,
            1502.0
          ],
          "confidence": 0.9927111268043518
        },
        {
          "text": "2.1",
          "bbox": [
            272.0,
            1517.0,
            343.0,
            1561.0
          ],
          "confidence": 0.998992919921875
        },
        {
          "text": "Project Technical Coordinators will be appointed by each the Parties for each Statement of Work. The Project Technical Coordinators will",
          "bbox": [
            444.0,
            1517.0,
            3020.0,
            1562.0
          ],
          "confidence": 0.9955620765686035
        },
        {
          "text": "be responsible for exchanging information with the other Party, coordinating any visits and arranging all other matters pertinent to that",
          "bbox": [
            446.0,
            1577.0,
            3021.0,
            1619.0
          ],
          "confidence": 0.9937794208526611
        },
        {
          "text": "Statement of Work.",
          "bbox": [
            448.0,
            1634.0,
            803.0,
            1672.0
          ],
          "confidence": 0.9995152354240417
        },
        {
          "text": "Master Joint Development Agreement iBio CC-Pharming",
          "bbox": [
            279.0,
            1741.0,
            1332.0,
            1789.0
          ],
          "confidence": 0.9914409518241882
        },
        {
          "text": "Page 2 of 12",
          "bbox": [
            2800.0,
            1743.0,
            3029.0,
            1787.0
          ],
          "confidence": 0.9996117949485779
        },
        {
          "text": "Source: IBIO, INC., 8-K, 3/13/2020",
          "bbox": [
            335.0,
            4440.0,
            1022.0,
            4477.0
          ],
          "confidence": 0.997024416923523
        }
      ]
    },
    {
      "id": "IbioInc_20200313_8-K_EX-10.1_12052678_EX-10.1_Development Agreement__Rofr/Rofo/Rofn_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Rofr/Rofo/Rofn\" that should be reviewed by a lawyer. Details: Is there a clause granting one party a right of first refusal, right of first offer or right of first negotiation to purchase, license, market, or distribute equity interest, technology, assets, products or services?",
      "answer_text": "The Creating Party grants to the other Party a time-limited first right to negotiate a commercial license to use, reproduce, display, and perform commercially valuable Copyright Materials for commercial purposes, and to distribute and/or sublicense such commercially valuable Copyright Materials to third parties.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.1",
          "bbox": [
            2800.0,
            283.0,
            3025.0,
            322.0
          ],
          "confidence": 0.9997009634971619
        },
        {
          "text": "NOTE: Certain information indicated with [***] in this document has been omitted from this exhibit because it is both (i) not material and (ii).",
          "bbox": [
            275.0,
            338.0,
            3027.0,
            384.0
          ],
          "confidence": 0.9894452691078186
        },
        {
          "text": "would be competitively harmful if publicly disclosed.",
          "bbox": [
            281.0,
            397.0,
            1258.0,
            440.0
          ],
          "confidence": 0.9874401688575745
        },
        {
          "text": "MASTER JOINT DEVELOPMENT AGREEMENT",
          "bbox": [
            1182.0,
            455.0,
            2121.0,
            492.0
          ],
          "confidence": 0.9990029335021973
        },
        {
          "text": "This Master Joint Development Agreement (\"Agreement\") is between iBio Inc., a Public corporation, with a location at iBio Inc., 600 Madison Ave,",
          "bbox": [
            275.0,
            504.0,
            3027.0,
            556.0
          ],
          "confidence": 0.9988492131233215
        },
        {
          "text": "Suite O1601 NY, NY 10022-1735 and Beijing CC-Pharming Ltd. of Beijing, China (\"CC-Pharming\"), a Chinese Corporation with a location at Shunyi",
          "bbox": [
            279.0,
            566.0,
            3027.0,
            609.0
          ],
          "confidence": 0.9916648864746094
        },
        {
          "text": "District, Beijing, China, 101312, each of the foregoing being individually referred to as a \"Party\" and collectively as the \"Parties\".",
          "bbox": [
            275.0,
            619.0,
            2664.0,
            665.0
          ],
          "confidence": 0.9942342042922974
        },
        {
          "text": "WHEREAS, iBio and CC-Pharming wish to establish a long-term working relationship for various joint research and development projects",
          "bbox": [
            444.0,
            676.0,
            3027.0,
            724.0
          ],
          "confidence": 0.9975687861442566
        },
        {
          "text": "(\"Projects) related to the development of various products, with the work for each Project to be described in a separate Statement of Work.",
          "bbox": [
            279.0,
            735.0,
            3029.0,
            777.0
          ],
          "confidence": 0.9938633441925049
        },
        {
          "text": "(\"SOw\") agreed by the Parties;",
          "bbox": [
            281.0,
            789.0,
            868.0,
            835.0
          ],
          "confidence": 0.9870513081550598
        },
        {
          "text": "WHEREAS, iBio has developed and owns proprietary technology used to produce proteins using proprietary vector systems that support",
          "bbox": [
            444.0,
            844.0,
            3029.0,
            892.0
          ],
          "confidence": 0.9940124750137329
        },
        {
          "text": "transient gene expression and protein production in plants, and iBio has developed and/or acquired additional proprietary biopharmaceutical",
          "bbox": [
            275.0,
            901.0,
            3031.0,
            947.0
          ],
          "confidence": 0.991813063621521
        },
        {
          "text": "technology, cGMP manufacturing expertise (\"iBio's Technology\"), and a facility design team that provides capabilities for application to the",
          "bbox": [
            279.0,
            963.0,
            3025.0,
            1000.0
          ],
          "confidence": 0.9882965087890625
        },
        {
          "text": "development of biotherapeutics; and.",
          "bbox": [
            279.0,
            1016.0,
            972.0,
            1058.0
          ],
          "confidence": 0.9877834320068359
        },
        {
          "text": "WHEREAs, iBio and CC-Pharming, wish to develop one or more biopharmaceuticals Product(s) (each a \"Product\") based on iBio's",
          "bbox": [
            446.0,
            1071.0,
            3029.0,
            1113.0
          ],
          "confidence": 0.987923264503479
        },
        {
          "text": "proprietary and patented plant-based protein production technology and know-how;.",
          "bbox": [
            275.0,
            1127.0,
            1861.0,
            1173.0
          ],
          "confidence": 0.9903185963630676
        },
        {
          "text": "WHEREAs, iBio and CC-Pharming wish to develop a long-term, mutually beneficial relationship for the production and sale of",
          "bbox": [
            448.0,
            1184.0,
            3030.0,
            1228.0
          ],
          "confidence": 0.9862040281295776
        },
        {
          "text": "biopharmaceuticals in China and to form a collaborative business venture to be majority owned and controlled by CC-Pharming and minority owned",
          "bbox": [
            277.0,
            1237.0,
            3029.0,
            1283.0
          ],
          "confidence": 0.9991291761398315
        },
        {
          "text": "by iBio; and",
          "bbox": [
            279.0,
            1296.0,
            508.0,
            1339.0
          ],
          "confidence": 0.9808014035224915
        },
        {
          "text": "NOw, THEREFORE, for good and valuable consideration as stated herein, the sufficiency of which is hereby expressly acknowledged by",
          "bbox": [
            442.0,
            1349.0,
            3023.0,
            1396.0
          ],
          "confidence": 0.99495530128479
        },
        {
          "text": "each Party, iBio and CC-Pharming agree as follows:",
          "bbox": [
            279.0,
            1409.0,
            1223.0,
            1451.0
          ],
          "confidence": 0.999891996383667
        },
        {
          "text": "1.0",
          "bbox": [
            274.0,
            1460.0,
            344.0,
            1508.0
          ],
          "confidence": 0.9981430172920227
        },
        {
          "text": "Limited Technology License",
          "bbox": [
            446.0,
            1464.0,
            982.0,
            1504.0
          ],
          "confidence": 0.9944542646408081
        },
        {
          "text": "1.1",
          "bbox": [
            274.0,
            1517.0,
            341.0,
            1561.0
          ],
          "confidence": 0.9970695972442627
        },
        {
          "text": "iBio hereby grants to CC-Pharming for the term of this Agreement, a nonexclusive, non- assignable, non-sublicensable, limited right and",
          "bbox": [
            448.0,
            1520.0,
            3021.0,
            1562.0
          ],
          "confidence": 0.996475875377655
        },
        {
          "text": "production of Product(s) and work to be performed under this Agreement. Each Product will be set forth in a separate Statement of Work",
          "bbox": [
            446.0,
            1630.0,
            3021.0,
            1676.0
          ],
          "confidence": 0.9869741201400757
        },
        {
          "text": "in the form set forth in Appendix A, which will be signed by representatives of each Party with signing authority. Each phase of the",
          "bbox": [
            446.0,
            1690.0,
            3020.0,
            1732.0
          ],
          "confidence": 0.9884188175201416
        },
        {
          "text": "project(s) will be subject to the terms and conditions set forth in this Agreement unless otherwise provided for or in a Statement of Work.",
          "bbox": [
            442.0,
            1738.0,
            3023.0,
            1793.0
          ],
          "confidence": 0.9936604499816895
        },
        {
          "text": "(\"SOw'), including but not limited to project purpose, project phases, and a project budget..",
          "bbox": [
            446.0,
            1800.0,
            2159.0,
            1846.0
          ],
          "confidence": 0.9933698773384094
        },
        {
          "text": "Master Joint Development Agreement iBio CC-Pharming",
          "bbox": [
            279.0,
            1910.0,
            1334.0,
            1957.0
          ],
          "confidence": 0.9935949444770813
        },
        {
          "text": "Page 1 of 12",
          "bbox": [
            2800.0,
            1911.0,
            3029.0,
            1955.0
          ],
          "confidence": 0.9980977177619934
        },
        {
          "text": "Source: IBIO, INC., 8-K, 3/13/2020",
          "bbox": [
            333.0,
            4435.0,
            1022.0,
            4479.0
          ],
          "confidence": 0.990613579750061
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "MASTER JOINT DEVELOPMENT AGREEMENT",
          "page": 0,
          "bbox": [
            1182.0,
            455.0,
            2121.0,
            492.0
          ]
        }
      ]
    },
    {
      "id": "IbioInc_20200313_8-K_EX-10.1_12052678_EX-10.1_Development Agreement__Rofr/Rofo/Rofn_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Rofr/Rofo/Rofn\" that should be reviewed by a lawyer. Details: Is there a clause granting one party a right of first refusal, right of first offer or right of first negotiation to purchase, license, market, or distribute equity interest, technology, assets, products or services?",
      "answer_text": "The Creating Party grants to the other Party a time-limited first right to negotiate a commercial license to use, reproduce, display, and perform commercially valuable Copyright Materials for commercial purposes, and to distribute and/or sublicense such commercially valuable Copyright Materials to third parties.",
      "page_number": 1,
      "words": [
        {
          "text": "1.2",
          "bbox": [
            274.0,
            283.0,
            343.0,
            327.0
          ],
          "confidence": 0.999828040599823
        },
        {
          "text": "No right or license is being conveyed to CC-Pharming to export Products or to otherwise use the Technology in any country other than",
          "bbox": [
            444.0,
            283.0,
            3020.0,
            327.0
          ],
          "confidence": 0.9960402250289917
        },
        {
          "text": "China.",
          "bbox": [
            444.0,
            338.0,
            564.0,
            382.0
          ],
          "confidence": 0.9998229146003723
        },
        {
          "text": "1.3",
          "bbox": [
            274.0,
            395.0,
            343.0,
            439.0
          ],
          "confidence": 0.9999030232429504
        },
        {
          "text": "iBio will work with CC-Pharming to perform a thorough Manufacturing Development Program based from an initial comprehensive two-",
          "bbox": [
            444.0,
            395.0,
            3020.0,
            440.0
          ],
          "confidence": 0.991921067237854
        },
        {
          "text": "day charrette to be held at its subsidiary iBio CDMO LLC facility in Bryan, Texas with the goals of CC-Pharming understanding the",
          "bbox": [
            446.0,
            451.0,
            3020.0,
            497.0
          ],
          "confidence": 0.9884581565856934
        },
        {
          "text": "definitive capital expenditure necessary and initiating a preliminary design for the first Product. iBio will provide an architect, construction",
          "bbox": [
            448.0,
            510.0,
            3021.0,
            554.0
          ],
          "confidence": 0.9959992170333862
        },
        {
          "text": "supervisor, mechanical engineer and process engineer with knowledge of the iBio CDMO facility currently in operation in Bryan, Texas.",
          "bbox": [
            448.0,
            566.0,
            2960.0,
            609.0
          ],
          "confidence": 0.9869726896286011
        },
        {
          "text": "1.4",
          "bbox": [
            274.0,
            619.0,
            343.0,
            663.0
          ],
          "confidence": 0.9999340176582336
        },
        {
          "text": "CC-Pharming hereby expressly acknowledges the validity and highly confidential and proprietary nature of iBio's Technology and",
          "bbox": [
            446.0,
            619.0,
            3021.0,
            665.0
          ],
          "confidence": 0.993236243724823
        },
        {
          "text": "technical information, know-how, documents, materials, software, vectors, constructs, trade secrets, and other valuable business or",
          "bbox": [
            446.0,
            676.0,
            3020.0,
            720.0
          ],
          "confidence": 0.9944519996643066
        },
        {
          "text": "scientific information that iBio will share with CC-Pharming in order to fulfill the purpose of this Agreement, namely, to form a legal",
          "bbox": [
            444.0,
            731.0,
            3021.0,
            777.0
          ],
          "confidence": 0.9856650829315186
        },
        {
          "text": "structure for a collaborative business venture in which CC-Pharming and iBio shall share revenue from product sales. iBio's double-digit",
          "bbox": [
            446.0,
            791.0,
            3021.0,
            833.0
          ],
          "confidence": 0.994662344455719
        },
        {
          "text": "percentage, minority interest in this structure will provide compensation to iBio for providing CC-Pharming with a license to use iBio's.",
          "bbox": [
            444.0,
            844.0,
            3021.0,
            892.0
          ],
          "confidence": 0.9963811039924622
        },
        {
          "text": "Technology and enabling know-how and will provide CC-Pharming with ongoing and mutually agreed technology transfer services",
          "bbox": [
            446.0,
            903.0,
            3021.0,
            945.0
          ],
          "confidence": 0.9966488480567932
        },
        {
          "text": "relevant to the evolving business and Product(s) of the collaborative venture.",
          "bbox": [
            446.0,
            963.0,
            1898.0,
            1000.0
          ],
          "confidence": 0.9989203214645386
        },
        {
          "text": "1.5",
          "bbox": [
            274.0,
            1011.0,
            344.0,
            1058.0
          ],
          "confidence": 0.9999009966850281
        },
        {
          "text": "The parties agree that the first product focus of the joint business collaboration will be a bio-better or bio-similar version of the",
          "bbox": [
            444.0,
            1012.0,
            3020.0,
            1058.0
          ],
          "confidence": 0.996626079082489
        },
        {
          "text": "therapeutic monoclonal antibody, rituximab. iBio will provide all necessary gene expression and vector technology for the transient.",
          "bbox": [
            446.0,
            1073.0,
            3023.0,
            1117.0
          ],
          "confidence": 0.9934687614440918
        },
        {
          "text": "expression and cGMP manufacturing of this protein in plants and will also provide pilot plant design services, construction consulting,",
          "bbox": [
            442.0,
            1124.0,
            3020.0,
            1175.0
          ],
          "confidence": 0.9993672966957092
        },
        {
          "text": "product and process development services, training, quality management system design, and clinical planning and regulatory consulting.",
          "bbox": [
            448.0,
            1186.0,
            3016.0,
            1228.0
          ],
          "confidence": 0.9921608567237854
        },
        {
          "text": "The tasks to be conducted in the first stage of the joint business collaboration will apply specifically to the rituximab product candidate",
          "bbox": [
            442.0,
            1235.0,
            3021.0,
            1286.0
          ],
          "confidence": 0.9976635575294495
        },
        {
          "text": "but will be applicable, in part, to additional products to be selected by mutual agreement for development, with the timeline for such work",
          "bbox": [
            448.0,
            1296.0,
            3021.0,
            1338.0
          ],
          "confidence": 0.9955782294273376
        },
        {
          "text": "to be determined by CC-Pharming.",
          "bbox": [
            444.0,
            1347.0,
            1082.0,
            1398.0
          ],
          "confidence": 0.9862340688705444
        },
        {
          "text": "1.5",
          "bbox": [
            274.0,
            1405.0,
            343.0,
            1449.0
          ],
          "confidence": 0.8620595335960388
        },
        {
          "text": "Any milestones or completion dates set forth in a Statement of Work will be estimates only, and are not binding on the Parties.",
          "bbox": [
            446.0,
            1405.0,
            2789.0,
            1451.0
          ],
          "confidence": 0.995090901851654
        },
        {
          "text": "2.0",
          "bbox": [
            270.0,
            1458.0,
            344.0,
            1508.0
          ],
          "confidence": 0.9997313022613525
        },
        {
          "text": "Coordinators and Governance Terms",
          "bbox": [
            450.0,
            1466.0,
            1144.0,
            1502.0
          ],
          "confidence": 0.9927111268043518
        },
        {
          "text": "2.1",
          "bbox": [
            272.0,
            1517.0,
            343.0,
            1561.0
          ],
          "confidence": 0.998992919921875
        },
        {
          "text": "Project Technical Coordinators will be appointed by each the Parties for each Statement of Work. The Project Technical Coordinators will",
          "bbox": [
            444.0,
            1517.0,
            3020.0,
            1562.0
          ],
          "confidence": 0.9955620765686035
        },
        {
          "text": "be responsible for exchanging information with the other Party, coordinating any visits and arranging all other matters pertinent to that",
          "bbox": [
            446.0,
            1577.0,
            3021.0,
            1619.0
          ],
          "confidence": 0.9937794208526611
        },
        {
          "text": "Statement of Work.",
          "bbox": [
            448.0,
            1634.0,
            803.0,
            1672.0
          ],
          "confidence": 0.9995152354240417
        },
        {
          "text": "Master Joint Development Agreement iBio CC-Pharming",
          "bbox": [
            279.0,
            1741.0,
            1332.0,
            1789.0
          ],
          "confidence": 0.9914409518241882
        },
        {
          "text": "Page 2 of 12",
          "bbox": [
            2800.0,
            1743.0,
            3029.0,
            1787.0
          ],
          "confidence": 0.9996117949485779
        },
        {
          "text": "Source: IBIO, INC., 8-K, 3/13/2020",
          "bbox": [
            335.0,
            4440.0,
            1022.0,
            4477.0
          ],
          "confidence": 0.997024416923523
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "IbioInc_20200313_8-K_EX-10.1_12052678_EX-10.1_Development Agreement__Anti-Assignment_1",
      "question": "Highlight the parts (if any) of this contract related to \"Anti-Assignment\" that should be reviewed by a lawyer. Details: Is consent or notice required of a party if the contract is assigned to a third party?",
      "answer_text": "Any unauthorized assignment of this Agreement is void.",
      "page_number": 1,
      "words": [
        {
          "text": "1.2",
          "bbox": [
            274.0,
            283.0,
            343.0,
            327.0
          ],
          "confidence": 0.999828040599823
        },
        {
          "text": "No right or license is being conveyed to CC-Pharming to export Products or to otherwise use the Technology in any country other than",
          "bbox": [
            444.0,
            283.0,
            3020.0,
            327.0
          ],
          "confidence": 0.9960402250289917
        },
        {
          "text": "China.",
          "bbox": [
            444.0,
            338.0,
            564.0,
            382.0
          ],
          "confidence": 0.9998229146003723
        },
        {
          "text": "1.3",
          "bbox": [
            274.0,
            395.0,
            343.0,
            439.0
          ],
          "confidence": 0.9999030232429504
        },
        {
          "text": "iBio will work with CC-Pharming to perform a thorough Manufacturing Development Program based from an initial comprehensive two-",
          "bbox": [
            444.0,
            395.0,
            3020.0,
            440.0
          ],
          "confidence": 0.991921067237854
        },
        {
          "text": "day charrette to be held at its subsidiary iBio CDMO LLC facility in Bryan, Texas with the goals of CC-Pharming understanding the",
          "bbox": [
            446.0,
            451.0,
            3020.0,
            497.0
          ],
          "confidence": 0.9884581565856934
        },
        {
          "text": "definitive capital expenditure necessary and initiating a preliminary design for the first Product. iBio will provide an architect, construction",
          "bbox": [
            448.0,
            510.0,
            3021.0,
            554.0
          ],
          "confidence": 0.9959992170333862
        },
        {
          "text": "supervisor, mechanical engineer and process engineer with knowledge of the iBio CDMO facility currently in operation in Bryan, Texas.",
          "bbox": [
            448.0,
            566.0,
            2960.0,
            609.0
          ],
          "confidence": 0.9869726896286011
        },
        {
          "text": "1.4",
          "bbox": [
            274.0,
            619.0,
            343.0,
            663.0
          ],
          "confidence": 0.9999340176582336
        },
        {
          "text": "CC-Pharming hereby expressly acknowledges the validity and highly confidential and proprietary nature of iBio's Technology and",
          "bbox": [
            446.0,
            619.0,
            3021.0,
            665.0
          ],
          "confidence": 0.993236243724823
        },
        {
          "text": "technical information, know-how, documents, materials, software, vectors, constructs, trade secrets, and other valuable business or",
          "bbox": [
            446.0,
            676.0,
            3020.0,
            720.0
          ],
          "confidence": 0.9944519996643066
        },
        {
          "text": "scientific information that iBio will share with CC-Pharming in order to fulfill the purpose of this Agreement, namely, to form a legal",
          "bbox": [
            444.0,
            731.0,
            3021.0,
            777.0
          ],
          "confidence": 0.9856650829315186
        },
        {
          "text": "structure for a collaborative business venture in which CC-Pharming and iBio shall share revenue from product sales. iBio's double-digit",
          "bbox": [
            446.0,
            791.0,
            3021.0,
            833.0
          ],
          "confidence": 0.994662344455719
        },
        {
          "text": "percentage, minority interest in this structure will provide compensation to iBio for providing CC-Pharming with a license to use iBio's.",
          "bbox": [
            444.0,
            844.0,
            3021.0,
            892.0
          ],
          "confidence": 0.9963811039924622
        },
        {
          "text": "Technology and enabling know-how and will provide CC-Pharming with ongoing and mutually agreed technology transfer services",
          "bbox": [
            446.0,
            903.0,
            3021.0,
            945.0
          ],
          "confidence": 0.9966488480567932
        },
        {
          "text": "relevant to the evolving business and Product(s) of the collaborative venture.",
          "bbox": [
            446.0,
            963.0,
            1898.0,
            1000.0
          ],
          "confidence": 0.9989203214645386
        },
        {
          "text": "1.5",
          "bbox": [
            274.0,
            1011.0,
            344.0,
            1058.0
          ],
          "confidence": 0.9999009966850281
        },
        {
          "text": "The parties agree that the first product focus of the joint business collaboration will be a bio-better or bio-similar version of the",
          "bbox": [
            444.0,
            1012.0,
            3020.0,
            1058.0
          ],
          "confidence": 0.996626079082489
        },
        {
          "text": "therapeutic monoclonal antibody, rituximab. iBio will provide all necessary gene expression and vector technology for the transient.",
          "bbox": [
            446.0,
            1073.0,
            3023.0,
            1117.0
          ],
          "confidence": 0.9934687614440918
        },
        {
          "text": "expression and cGMP manufacturing of this protein in plants and will also provide pilot plant design services, construction consulting,",
          "bbox": [
            442.0,
            1124.0,
            3020.0,
            1175.0
          ],
          "confidence": 0.9993672966957092
        },
        {
          "text": "product and process development services, training, quality management system design, and clinical planning and regulatory consulting.",
          "bbox": [
            448.0,
            1186.0,
            3016.0,
            1228.0
          ],
          "confidence": 0.9921608567237854
        },
        {
          "text": "The tasks to be conducted in the first stage of the joint business collaboration will apply specifically to the rituximab product candidate",
          "bbox": [
            442.0,
            1235.0,
            3021.0,
            1286.0
          ],
          "confidence": 0.9976635575294495
        },
        {
          "text": "but will be applicable, in part, to additional products to be selected by mutual agreement for development, with the timeline for such work",
          "bbox": [
            448.0,
            1296.0,
            3021.0,
            1338.0
          ],
          "confidence": 0.9955782294273376
        },
        {
          "text": "to be determined by CC-Pharming.",
          "bbox": [
            444.0,
            1347.0,
            1082.0,
            1398.0
          ],
          "confidence": 0.9862340688705444
        },
        {
          "text": "1.5",
          "bbox": [
            274.0,
            1405.0,
            343.0,
            1449.0
          ],
          "confidence": 0.8620595335960388
        },
        {
          "text": "Any milestones or completion dates set forth in a Statement of Work will be estimates only, and are not binding on the Parties.",
          "bbox": [
            446.0,
            1405.0,
            2789.0,
            1451.0
          ],
          "confidence": 0.995090901851654
        },
        {
          "text": "2.0",
          "bbox": [
            270.0,
            1458.0,
            344.0,
            1508.0
          ],
          "confidence": 0.9997313022613525
        },
        {
          "text": "Coordinators and Governance Terms",
          "bbox": [
            450.0,
            1466.0,
            1144.0,
            1502.0
          ],
          "confidence": 0.9927111268043518
        },
        {
          "text": "2.1",
          "bbox": [
            272.0,
            1517.0,
            343.0,
            1561.0
          ],
          "confidence": 0.998992919921875
        },
        {
          "text": "Project Technical Coordinators will be appointed by each the Parties for each Statement of Work. The Project Technical Coordinators will",
          "bbox": [
            444.0,
            1517.0,
            3020.0,
            1562.0
          ],
          "confidence": 0.9955620765686035
        },
        {
          "text": "be responsible for exchanging information with the other Party, coordinating any visits and arranging all other matters pertinent to that",
          "bbox": [
            446.0,
            1577.0,
            3021.0,
            1619.0
          ],
          "confidence": 0.9937794208526611
        },
        {
          "text": "Statement of Work.",
          "bbox": [
            448.0,
            1634.0,
            803.0,
            1672.0
          ],
          "confidence": 0.9995152354240417
        },
        {
          "text": "Master Joint Development Agreement iBio CC-Pharming",
          "bbox": [
            279.0,
            1741.0,
            1332.0,
            1789.0
          ],
          "confidence": 0.9914409518241882
        },
        {
          "text": "Page 2 of 12",
          "bbox": [
            2800.0,
            1743.0,
            3029.0,
            1787.0
          ],
          "confidence": 0.9996117949485779
        },
        {
          "text": "Source: IBIO, INC., 8-K, 3/13/2020",
          "bbox": [
            335.0,
            4440.0,
            1022.0,
            4477.0
          ],
          "confidence": 0.997024416923523
        }
      ]
    },
    {
      "id": "IbioInc_20200313_8-K_EX-10.1_12052678_EX-10.1_Development Agreement__Anti-Assignment_3",
      "question": "Highlight the parts (if any) of this contract related to \"Anti-Assignment\" that should be reviewed by a lawyer. Details: Is consent or notice required of a party if the contract is assigned to a third party?",
      "answer_text": "Neither Party may assign its rights or delegate any of its duties under this Agreement without the prior written consent of the other Party.",
      "page_number": 3,
      "words": [
        {
          "text": "2.5",
          "bbox": [
            270.0,
            280.0,
            344.0,
            329.0
          ],
          "confidence": 0.9998720288276672
        },
        {
          "text": "Each Party may change its Agreement Administrators, at any time, with written notice to the other Party.",
          "bbox": [
            446.0,
            283.0,
            2378.0,
            329.0
          ],
          "confidence": 0.9910029768943787
        },
        {
          "text": "3.0",
          "bbox": [
            272.0,
            340.0,
            343.0,
            382.0
          ],
          "confidence": 0.9999339580535889
        },
        {
          "text": "Costs and Expenses",
          "bbox": [
            446.0,
            342.0,
            825.0,
            382.0
          ],
          "confidence": 0.9999476671218872
        },
        {
          "text": "3.1",
          "bbox": [
            272.0,
            395.0,
            343.0,
            439.0
          ],
          "confidence": 0.9999558329582214
        },
        {
          "text": "Upon execution of this Agreement and acceptance of iBio's proposal for the development of a Plant-Made Rituximab, and in consideration",
          "bbox": [
            448.0,
            398.0,
            3020.0,
            440.0
          ],
          "confidence": 0.9943196177482605
        },
        {
          "text": "for providing the technology transfer contemplated herein, CC-Pharming shall pay iBio [***], which shall be paid as follows:",
          "bbox": [
            444.0,
            451.0,
            2759.0,
            497.0
          ],
          "confidence": 0.9941513538360596
        },
        {
          "text": "3.1.1",
          "bbox": [
            444.0,
            508.0,
            531.0,
            550.0
          ],
          "confidence": 0.9998992681503296
        },
        {
          "text": "First payment of [***] is required to initiate the project: [***].",
          "bbox": [
            613.0,
            510.0,
            1769.0,
            554.0
          ],
          "confidence": 0.9945611953735352
        },
        {
          "text": "3.1.2",
          "bbox": [
            442.0,
            565.0,
            535.0,
            607.0
          ],
          "confidence": 0.9999285936355591
        },
        {
          "text": "Second payment of [***]. Due upon presentation of the following deliverables:",
          "bbox": [
            614.0,
            566.0,
            2090.0,
            610.0
          ],
          "confidence": 0.9994739890098572
        },
        {
          "text": "a)",
          "bbox": [
            613.0,
            625.0,
            658.0,
            665.0
          ],
          "confidence": 0.9990170001983643
        },
        {
          "text": "Detailed design drawings of the pilot plant;.",
          "bbox": [
            691.0,
            621.0,
            1504.0,
            665.0
          ],
          "confidence": 0.9937103390693665
        },
        {
          "text": "b)",
          "bbox": [
            609.0,
            674.0,
            662.0,
            722.0
          ],
          "confidence": 0.9977127313613892
        },
        {
          "text": "Schematic design of the commercial facility;.",
          "bbox": [
            692.0,
            676.0,
            1510.0,
            722.0
          ],
          "confidence": 0.9897212386131287
        },
        {
          "text": "c)",
          "bbox": [
            613.0,
            736.0,
            652.0,
            778.0
          ],
          "confidence": 0.9976531267166138
        },
        {
          "text": "Purified antibody for pre-clinical testing and development; and",
          "bbox": [
            694.0,
            735.0,
            1869.0,
            777.0
          ],
          "confidence": 0.9880231022834778
        },
        {
          "text": "d)",
          "bbox": [
            614.0,
            789.0,
            658.0,
            835.0
          ],
          "confidence": 0.9987993240356445
        },
        {
          "text": "The quality management system (QMS) development up to and including governance documents and governance standard",
          "bbox": [
            694.0,
            791.0,
            3029.0,
            835.0
          ],
          "confidence": 0.9927464723587036
        },
        {
          "text": "operating procedures (SOP's).",
          "bbox": [
            698.0,
            844.0,
            1260.0,
            892.0
          ],
          "confidence": 0.9994139075279236
        },
        {
          "text": "3.1.3",
          "bbox": [
            442.0,
            901.0,
            535.0,
            943.0
          ],
          "confidence": 0.9999394416809082
        },
        {
          "text": "Final payment of [***], due upon presentation of the following deliverables:",
          "bbox": [
            614.0,
            903.0,
            2034.0,
            945.0
          ],
          "confidence": 0.9988285899162292
        },
        {
          "text": "a)",
          "bbox": [
            614.0,
            965.0,
            652.0,
            1000.0
          ],
          "confidence": 0.998231053352356
        },
        {
          "text": "Detailed Design drawings for the commercial facility;",
          "bbox": [
            692.0,
            959.0,
            1678.0,
            1000.0
          ],
          "confidence": 0.9978647828102112
        },
        {
          "text": "b)",
          "bbox": [
            611.0,
            1014.0,
            658.0,
            1056.0
          ],
          "confidence": 0.997105062007904
        },
        {
          "text": "Completion of QMS documentation for rituximab including batch records, release documents, and assay SOPs;",
          "bbox": [
            692.0,
            1014.0,
            2759.0,
            1058.0
          ],
          "confidence": 0.9970455169677734
        },
        {
          "text": "c)",
          "bbox": [
            611.0,
            1073.0,
            652.0,
            1117.0
          ],
          "confidence": 0.9969731569290161
        },
        {
          "text": "Completion of all training sessions and training documentation;",
          "bbox": [
            696.0,
            1073.0,
            1887.0,
            1115.0
          ],
          "confidence": 0.9993488788604736
        },
        {
          "text": "d)",
          "bbox": [
            613.0,
            1126.0,
            654.0,
            1171.0
          ],
          "confidence": 0.9987305998802185
        },
        {
          "text": "Delivery of antibody drug substance for clinical trials; and",
          "bbox": [
            694.0,
            1126.0,
            1789.0,
            1170.0
          ],
          "confidence": 0.9840881824493408
        },
        {
          "text": "e)",
          "bbox": [
            613.0,
            1184.0,
            652.0,
            1226.0
          ],
          "confidence": 0.9990893602371216
        },
        {
          "text": "Completion of a chemistry, manufacturing, and controls (CMC) document to support an (investigational new drug",
          "bbox": [
            696.0,
            1182.0,
            3027.0,
            1228.0
          ],
          "confidence": 0.9888213872909546
        },
        {
          "text": "application (IND) or equivalent.",
          "bbox": [
            700.0,
            1237.0,
            1289.0,
            1285.0
          ],
          "confidence": 0.9910324215888977
        },
        {
          "text": "4.0",
          "bbox": [
            274.0,
            1292.0,
            344.0,
            1339.0
          ],
          "confidence": 0.9997520446777344
        },
        {
          "text": "Inventions",
          "bbox": [
            444.0,
            1296.0,
            643.0,
            1334.0
          ],
          "confidence": 0.9856982231140137
        },
        {
          "text": "4.1",
          "bbox": [
            274.0,
            1349.0,
            343.0,
            1392.0
          ],
          "confidence": 0.9998094439506531
        },
        {
          "text": "Inventorship of inventions, developments, or discoveries first conceived or actually reduced to practice under this Agreement.",
          "bbox": [
            444.0,
            1350.0,
            3021.0,
            1394.0
          ],
          "confidence": 0.99659264087677
        },
        {
          "text": "(\"Agreement Inventions\") will be determined under U.S. Patent Law. All inventions, developments, or discoveries made solely by iBio.",
          "bbox": [
            446.0,
            1405.0,
            3020.0,
            1451.0
          ],
          "confidence": 0.9859450459480286
        },
        {
          "text": "prior to this Agreement is, and shall be, the sole property of iBio. All inventions, developments, or discoveries made solely by CC-",
          "bbox": [
            446.0,
            1462.0,
            3016.0,
            1508.0
          ],
          "confidence": 0.9891068339347839
        },
        {
          "text": "Pharming thereof prior to this Agreement is, and shall be, the sole property of CC-Pharming",
          "bbox": [
            446.0,
            1517.0,
            2148.0,
            1564.0
          ],
          "confidence": 0.9925838708877563
        },
        {
          "text": "4.2",
          "bbox": [
            274.0,
            1575.0,
            343.0,
            1619.0
          ],
          "confidence": 0.9996762871742249
        },
        {
          "text": "All rights to inventions, patentable or non-patentable, made solely by employees of iBio during the term of this Agreement shall belong",
          "bbox": [
            446.0,
            1575.0,
            3020.0,
            1621.0
          ],
          "confidence": 0.9978708028793335
        },
        {
          "text": "solely to iBio. All rights to inventions, patentable or non-patentable, made solely by employees of CC-Pharming during the term of this",
          "bbox": [
            448.0,
            1634.0,
            3021.0,
            1676.0
          ],
          "confidence": 0.9939596652984619
        },
        {
          "text": "Agreement shall belong solely to CC-Pharming. All rights to Agreement Inventions, patentable or non-patentable, made jointly by",
          "bbox": [
            448.0,
            1690.0,
            3018.0,
            1732.0
          ],
          "confidence": 0.9912444949150085
        },
        {
          "text": "employees of iBio and employees of CC-Pharming (\"Joint Inventions\") will belong jointly to iBio and CC-Pharming, with inventorship.",
          "bbox": [
            446.0,
            1743.0,
            3020.0,
            1789.0
          ],
          "confidence": 0.9849509000778198
        },
        {
          "text": "determined as described in 35 U.S.C. s 262 and (Chin Patent Law). The Parties contemplate that each will benefit from Joint Inventions, as",
          "bbox": [
            446.0,
            1798.0,
            3021.0,
            1844.0
          ],
          "confidence": 0.9943764805793762
        },
        {
          "text": "such, iBio will be responsible for direct control over the drafting and prosecution of any patents to Joint Inventions, with copy to CC-.",
          "bbox": [
            448.0,
            1857.0,
            3016.0,
            1900.0
          ],
          "confidence": 0.9833199977874756
        },
        {
          "text": "Pharming. The parties shall share equally in the costs of patent protection for Joint Inventions.",
          "bbox": [
            444.0,
            1911.0,
            2211.0,
            1955.0
          ],
          "confidence": 0.9975303411483765
        },
        {
          "text": "Master Joint Development Agreement iBio CC-Pharming.",
          "bbox": [
            277.0,
            2017.0,
            1336.0,
            2072.0
          ],
          "confidence": 0.988772988319397
        },
        {
          "text": "Page 4 of 12",
          "bbox": [
            2798.0,
            2021.0,
            3029.0,
            2071.0
          ],
          "confidence": 0.9983462691307068
        },
        {
          "text": "Source: IBIO, INC., 8-K, 3/13/2020",
          "bbox": [
            333.0,
            4435.0,
            1022.0,
            4479.0
          ],
          "confidence": 0.9961855411529541
        }
      ]
    },
    {
      "id": "IbioInc_20200313_8-K_EX-10.1_12052678_EX-10.1_Development Agreement__Joint Ip Ownership_1",
      "question": "Highlight the parts (if any) of this contract related to \"Joint Ip Ownership\" that should be reviewed by a lawyer. Details: Is there any clause providing for joint or shared ownership of intellectual property between the parties to the contract?",
      "answer_text": "Copyright Materials that are jointly created by the Parties shall be jointly owned.",
      "page_number": 1,
      "words": [
        {
          "text": "1.2",
          "bbox": [
            274.0,
            283.0,
            343.0,
            327.0
          ],
          "confidence": 0.999828040599823
        },
        {
          "text": "No right or license is being conveyed to CC-Pharming to export Products or to otherwise use the Technology in any country other than",
          "bbox": [
            444.0,
            283.0,
            3020.0,
            327.0
          ],
          "confidence": 0.9960402250289917
        },
        {
          "text": "China.",
          "bbox": [
            444.0,
            338.0,
            564.0,
            382.0
          ],
          "confidence": 0.9998229146003723
        },
        {
          "text": "1.3",
          "bbox": [
            274.0,
            395.0,
            343.0,
            439.0
          ],
          "confidence": 0.9999030232429504
        },
        {
          "text": "iBio will work with CC-Pharming to perform a thorough Manufacturing Development Program based from an initial comprehensive two-",
          "bbox": [
            444.0,
            395.0,
            3020.0,
            440.0
          ],
          "confidence": 0.991921067237854
        },
        {
          "text": "day charrette to be held at its subsidiary iBio CDMO LLC facility in Bryan, Texas with the goals of CC-Pharming understanding the",
          "bbox": [
            446.0,
            451.0,
            3020.0,
            497.0
          ],
          "confidence": 0.9884581565856934
        },
        {
          "text": "definitive capital expenditure necessary and initiating a preliminary design for the first Product. iBio will provide an architect, construction",
          "bbox": [
            448.0,
            510.0,
            3021.0,
            554.0
          ],
          "confidence": 0.9959992170333862
        },
        {
          "text": "supervisor, mechanical engineer and process engineer with knowledge of the iBio CDMO facility currently in operation in Bryan, Texas.",
          "bbox": [
            448.0,
            566.0,
            2960.0,
            609.0
          ],
          "confidence": 0.9869726896286011
        },
        {
          "text": "1.4",
          "bbox": [
            274.0,
            619.0,
            343.0,
            663.0
          ],
          "confidence": 0.9999340176582336
        },
        {
          "text": "CC-Pharming hereby expressly acknowledges the validity and highly confidential and proprietary nature of iBio's Technology and",
          "bbox": [
            446.0,
            619.0,
            3021.0,
            665.0
          ],
          "confidence": 0.993236243724823
        },
        {
          "text": "technical information, know-how, documents, materials, software, vectors, constructs, trade secrets, and other valuable business or",
          "bbox": [
            446.0,
            676.0,
            3020.0,
            720.0
          ],
          "confidence": 0.9944519996643066
        },
        {
          "text": "scientific information that iBio will share with CC-Pharming in order to fulfill the purpose of this Agreement, namely, to form a legal",
          "bbox": [
            444.0,
            731.0,
            3021.0,
            777.0
          ],
          "confidence": 0.9856650829315186
        },
        {
          "text": "structure for a collaborative business venture in which CC-Pharming and iBio shall share revenue from product sales. iBio's double-digit",
          "bbox": [
            446.0,
            791.0,
            3021.0,
            833.0
          ],
          "confidence": 0.994662344455719
        },
        {
          "text": "percentage, minority interest in this structure will provide compensation to iBio for providing CC-Pharming with a license to use iBio's.",
          "bbox": [
            444.0,
            844.0,
            3021.0,
            892.0
          ],
          "confidence": 0.9963811039924622
        },
        {
          "text": "Technology and enabling know-how and will provide CC-Pharming with ongoing and mutually agreed technology transfer services",
          "bbox": [
            446.0,
            903.0,
            3021.0,
            945.0
          ],
          "confidence": 0.9966488480567932
        },
        {
          "text": "relevant to the evolving business and Product(s) of the collaborative venture.",
          "bbox": [
            446.0,
            963.0,
            1898.0,
            1000.0
          ],
          "confidence": 0.9989203214645386
        },
        {
          "text": "1.5",
          "bbox": [
            274.0,
            1011.0,
            344.0,
            1058.0
          ],
          "confidence": 0.9999009966850281
        },
        {
          "text": "The parties agree that the first product focus of the joint business collaboration will be a bio-better or bio-similar version of the",
          "bbox": [
            444.0,
            1012.0,
            3020.0,
            1058.0
          ],
          "confidence": 0.996626079082489
        },
        {
          "text": "therapeutic monoclonal antibody, rituximab. iBio will provide all necessary gene expression and vector technology for the transient.",
          "bbox": [
            446.0,
            1073.0,
            3023.0,
            1117.0
          ],
          "confidence": 0.9934687614440918
        },
        {
          "text": "expression and cGMP manufacturing of this protein in plants and will also provide pilot plant design services, construction consulting,",
          "bbox": [
            442.0,
            1124.0,
            3020.0,
            1175.0
          ],
          "confidence": 0.9993672966957092
        },
        {
          "text": "product and process development services, training, quality management system design, and clinical planning and regulatory consulting.",
          "bbox": [
            448.0,
            1186.0,
            3016.0,
            1228.0
          ],
          "confidence": 0.9921608567237854
        },
        {
          "text": "The tasks to be conducted in the first stage of the joint business collaboration will apply specifically to the rituximab product candidate",
          "bbox": [
            442.0,
            1235.0,
            3021.0,
            1286.0
          ],
          "confidence": 0.9976635575294495
        },
        {
          "text": "but will be applicable, in part, to additional products to be selected by mutual agreement for development, with the timeline for such work",
          "bbox": [
            448.0,
            1296.0,
            3021.0,
            1338.0
          ],
          "confidence": 0.9955782294273376
        },
        {
          "text": "to be determined by CC-Pharming.",
          "bbox": [
            444.0,
            1347.0,
            1082.0,
            1398.0
          ],
          "confidence": 0.9862340688705444
        },
        {
          "text": "1.5",
          "bbox": [
            274.0,
            1405.0,
            343.0,
            1449.0
          ],
          "confidence": 0.8620595335960388
        },
        {
          "text": "Any milestones or completion dates set forth in a Statement of Work will be estimates only, and are not binding on the Parties.",
          "bbox": [
            446.0,
            1405.0,
            2789.0,
            1451.0
          ],
          "confidence": 0.995090901851654
        },
        {
          "text": "2.0",
          "bbox": [
            270.0,
            1458.0,
            344.0,
            1508.0
          ],
          "confidence": 0.9997313022613525
        },
        {
          "text": "Coordinators and Governance Terms",
          "bbox": [
            450.0,
            1466.0,
            1144.0,
            1502.0
          ],
          "confidence": 0.9927111268043518
        },
        {
          "text": "2.1",
          "bbox": [
            272.0,
            1517.0,
            343.0,
            1561.0
          ],
          "confidence": 0.998992919921875
        },
        {
          "text": "Project Technical Coordinators will be appointed by each the Parties for each Statement of Work. The Project Technical Coordinators will",
          "bbox": [
            444.0,
            1517.0,
            3020.0,
            1562.0
          ],
          "confidence": 0.9955620765686035
        },
        {
          "text": "be responsible for exchanging information with the other Party, coordinating any visits and arranging all other matters pertinent to that",
          "bbox": [
            446.0,
            1577.0,
            3021.0,
            1619.0
          ],
          "confidence": 0.9937794208526611
        },
        {
          "text": "Statement of Work.",
          "bbox": [
            448.0,
            1634.0,
            803.0,
            1672.0
          ],
          "confidence": 0.9995152354240417
        },
        {
          "text": "Master Joint Development Agreement iBio CC-Pharming",
          "bbox": [
            279.0,
            1741.0,
            1332.0,
            1789.0
          ],
          "confidence": 0.9914409518241882
        },
        {
          "text": "Page 2 of 12",
          "bbox": [
            2800.0,
            1743.0,
            3029.0,
            1787.0
          ],
          "confidence": 0.9996117949485779
        },
        {
          "text": "Source: IBIO, INC., 8-K, 3/13/2020",
          "bbox": [
            335.0,
            4440.0,
            1022.0,
            4477.0
          ],
          "confidence": 0.997024416923523
        }
      ]
    },
    {
      "id": "IbioInc_20200313_8-K_EX-10.1_12052678_EX-10.1_Development Agreement__Joint Ip Ownership_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Joint Ip Ownership\" that should be reviewed by a lawyer. Details: Is there any clause providing for joint or shared ownership of intellectual property between the parties to the contract?",
      "answer_text": "All rights to Agreement Inventions, patentable or non-patentable, made jointly by employees of iBio and employees of CC-Pharming (\"Joint Inventions\") will belong jointly to iBio and CC-Pharming, with inventorship determined as described in 35 U.S.C. § 262 and (Chin Patent Law).",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.1",
          "bbox": [
            2800.0,
            283.0,
            3025.0,
            322.0
          ],
          "confidence": 0.9997009634971619
        },
        {
          "text": "NOTE: Certain information indicated with [***] in this document has been omitted from this exhibit because it is both (i) not material and (ii).",
          "bbox": [
            275.0,
            338.0,
            3027.0,
            384.0
          ],
          "confidence": 0.9894452691078186
        },
        {
          "text": "would be competitively harmful if publicly disclosed.",
          "bbox": [
            281.0,
            397.0,
            1258.0,
            440.0
          ],
          "confidence": 0.9874401688575745
        },
        {
          "text": "MASTER JOINT DEVELOPMENT AGREEMENT",
          "bbox": [
            1182.0,
            455.0,
            2121.0,
            492.0
          ],
          "confidence": 0.9990029335021973
        },
        {
          "text": "This Master Joint Development Agreement (\"Agreement\") is between iBio Inc., a Public corporation, with a location at iBio Inc., 600 Madison Ave,",
          "bbox": [
            275.0,
            504.0,
            3027.0,
            556.0
          ],
          "confidence": 0.9988492131233215
        },
        {
          "text": "Suite O1601 NY, NY 10022-1735 and Beijing CC-Pharming Ltd. of Beijing, China (\"CC-Pharming\"), a Chinese Corporation with a location at Shunyi",
          "bbox": [
            279.0,
            566.0,
            3027.0,
            609.0
          ],
          "confidence": 0.9916648864746094
        },
        {
          "text": "District, Beijing, China, 101312, each of the foregoing being individually referred to as a \"Party\" and collectively as the \"Parties\".",
          "bbox": [
            275.0,
            619.0,
            2664.0,
            665.0
          ],
          "confidence": 0.9942342042922974
        },
        {
          "text": "WHEREAS, iBio and CC-Pharming wish to establish a long-term working relationship for various joint research and development projects",
          "bbox": [
            444.0,
            676.0,
            3027.0,
            724.0
          ],
          "confidence": 0.9975687861442566
        },
        {
          "text": "(\"Projects) related to the development of various products, with the work for each Project to be described in a separate Statement of Work.",
          "bbox": [
            279.0,
            735.0,
            3029.0,
            777.0
          ],
          "confidence": 0.9938633441925049
        },
        {
          "text": "(\"SOw\") agreed by the Parties;",
          "bbox": [
            281.0,
            789.0,
            868.0,
            835.0
          ],
          "confidence": 0.9870513081550598
        },
        {
          "text": "WHEREAS, iBio has developed and owns proprietary technology used to produce proteins using proprietary vector systems that support",
          "bbox": [
            444.0,
            844.0,
            3029.0,
            892.0
          ],
          "confidence": 0.9940124750137329
        },
        {
          "text": "transient gene expression and protein production in plants, and iBio has developed and/or acquired additional proprietary biopharmaceutical",
          "bbox": [
            275.0,
            901.0,
            3031.0,
            947.0
          ],
          "confidence": 0.991813063621521
        },
        {
          "text": "technology, cGMP manufacturing expertise (\"iBio's Technology\"), and a facility design team that provides capabilities for application to the",
          "bbox": [
            279.0,
            963.0,
            3025.0,
            1000.0
          ],
          "confidence": 0.9882965087890625
        },
        {
          "text": "development of biotherapeutics; and.",
          "bbox": [
            279.0,
            1016.0,
            972.0,
            1058.0
          ],
          "confidence": 0.9877834320068359
        },
        {
          "text": "WHEREAs, iBio and CC-Pharming, wish to develop one or more biopharmaceuticals Product(s) (each a \"Product\") based on iBio's",
          "bbox": [
            446.0,
            1071.0,
            3029.0,
            1113.0
          ],
          "confidence": 0.987923264503479
        },
        {
          "text": "proprietary and patented plant-based protein production technology and know-how;.",
          "bbox": [
            275.0,
            1127.0,
            1861.0,
            1173.0
          ],
          "confidence": 0.9903185963630676
        },
        {
          "text": "WHEREAs, iBio and CC-Pharming wish to develop a long-term, mutually beneficial relationship for the production and sale of",
          "bbox": [
            448.0,
            1184.0,
            3030.0,
            1228.0
          ],
          "confidence": 0.9862040281295776
        },
        {
          "text": "biopharmaceuticals in China and to form a collaborative business venture to be majority owned and controlled by CC-Pharming and minority owned",
          "bbox": [
            277.0,
            1237.0,
            3029.0,
            1283.0
          ],
          "confidence": 0.9991291761398315
        },
        {
          "text": "by iBio; and",
          "bbox": [
            279.0,
            1296.0,
            508.0,
            1339.0
          ],
          "confidence": 0.9808014035224915
        },
        {
          "text": "NOw, THEREFORE, for good and valuable consideration as stated herein, the sufficiency of which is hereby expressly acknowledged by",
          "bbox": [
            442.0,
            1349.0,
            3023.0,
            1396.0
          ],
          "confidence": 0.99495530128479
        },
        {
          "text": "each Party, iBio and CC-Pharming agree as follows:",
          "bbox": [
            279.0,
            1409.0,
            1223.0,
            1451.0
          ],
          "confidence": 0.999891996383667
        },
        {
          "text": "1.0",
          "bbox": [
            274.0,
            1460.0,
            344.0,
            1508.0
          ],
          "confidence": 0.9981430172920227
        },
        {
          "text": "Limited Technology License",
          "bbox": [
            446.0,
            1464.0,
            982.0,
            1504.0
          ],
          "confidence": 0.9944542646408081
        },
        {
          "text": "1.1",
          "bbox": [
            274.0,
            1517.0,
            341.0,
            1561.0
          ],
          "confidence": 0.9970695972442627
        },
        {
          "text": "iBio hereby grants to CC-Pharming for the term of this Agreement, a nonexclusive, non- assignable, non-sublicensable, limited right and",
          "bbox": [
            448.0,
            1520.0,
            3021.0,
            1562.0
          ],
          "confidence": 0.996475875377655
        },
        {
          "text": "production of Product(s) and work to be performed under this Agreement. Each Product will be set forth in a separate Statement of Work",
          "bbox": [
            446.0,
            1630.0,
            3021.0,
            1676.0
          ],
          "confidence": 0.9869741201400757
        },
        {
          "text": "in the form set forth in Appendix A, which will be signed by representatives of each Party with signing authority. Each phase of the",
          "bbox": [
            446.0,
            1690.0,
            3020.0,
            1732.0
          ],
          "confidence": 0.9884188175201416
        },
        {
          "text": "project(s) will be subject to the terms and conditions set forth in this Agreement unless otherwise provided for or in a Statement of Work.",
          "bbox": [
            442.0,
            1738.0,
            3023.0,
            1793.0
          ],
          "confidence": 0.9936604499816895
        },
        {
          "text": "(\"SOw'), including but not limited to project purpose, project phases, and a project budget..",
          "bbox": [
            446.0,
            1800.0,
            2159.0,
            1846.0
          ],
          "confidence": 0.9933698773384094
        },
        {
          "text": "Master Joint Development Agreement iBio CC-Pharming",
          "bbox": [
            279.0,
            1910.0,
            1334.0,
            1957.0
          ],
          "confidence": 0.9935949444770813
        },
        {
          "text": "Page 1 of 12",
          "bbox": [
            2800.0,
            1911.0,
            3029.0,
            1955.0
          ],
          "confidence": 0.9980977177619934
        },
        {
          "text": "Source: IBIO, INC., 8-K, 3/13/2020",
          "bbox": [
            333.0,
            4435.0,
            1022.0,
            4479.0
          ],
          "confidence": 0.990613579750061
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "MASTER JOINT DEVELOPMENT AGREEMENT",
          "page": 0,
          "bbox": [
            1182.0,
            455.0,
            2121.0,
            492.0
          ]
        }
      ]
    },
    {
      "id": "IbioInc_20200313_8-K_EX-10.1_12052678_EX-10.1_Development Agreement__Joint Ip Ownership_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Joint Ip Ownership\" that should be reviewed by a lawyer. Details: Is there any clause providing for joint or shared ownership of intellectual property between the parties to the contract?",
      "answer_text": "All rights to Agreement Inventions, patentable or non-patentable, made jointly by employees of iBio and employees of CC-Pharming (\"Joint Inventions\") will belong jointly to iBio and CC-Pharming, with inventorship determined as described in 35 U.S.C. § 262 and (Chin Patent Law).",
      "page_number": 1,
      "words": [
        {
          "text": "1.2",
          "bbox": [
            274.0,
            283.0,
            343.0,
            327.0
          ],
          "confidence": 0.999828040599823
        },
        {
          "text": "No right or license is being conveyed to CC-Pharming to export Products or to otherwise use the Technology in any country other than",
          "bbox": [
            444.0,
            283.0,
            3020.0,
            327.0
          ],
          "confidence": 0.9960402250289917
        },
        {
          "text": "China.",
          "bbox": [
            444.0,
            338.0,
            564.0,
            382.0
          ],
          "confidence": 0.9998229146003723
        },
        {
          "text": "1.3",
          "bbox": [
            274.0,
            395.0,
            343.0,
            439.0
          ],
          "confidence": 0.9999030232429504
        },
        {
          "text": "iBio will work with CC-Pharming to perform a thorough Manufacturing Development Program based from an initial comprehensive two-",
          "bbox": [
            444.0,
            395.0,
            3020.0,
            440.0
          ],
          "confidence": 0.991921067237854
        },
        {
          "text": "day charrette to be held at its subsidiary iBio CDMO LLC facility in Bryan, Texas with the goals of CC-Pharming understanding the",
          "bbox": [
            446.0,
            451.0,
            3020.0,
            497.0
          ],
          "confidence": 0.9884581565856934
        },
        {
          "text": "definitive capital expenditure necessary and initiating a preliminary design for the first Product. iBio will provide an architect, construction",
          "bbox": [
            448.0,
            510.0,
            3021.0,
            554.0
          ],
          "confidence": 0.9959992170333862
        },
        {
          "text": "supervisor, mechanical engineer and process engineer with knowledge of the iBio CDMO facility currently in operation in Bryan, Texas.",
          "bbox": [
            448.0,
            566.0,
            2960.0,
            609.0
          ],
          "confidence": 0.9869726896286011
        },
        {
          "text": "1.4",
          "bbox": [
            274.0,
            619.0,
            343.0,
            663.0
          ],
          "confidence": 0.9999340176582336
        },
        {
          "text": "CC-Pharming hereby expressly acknowledges the validity and highly confidential and proprietary nature of iBio's Technology and",
          "bbox": [
            446.0,
            619.0,
            3021.0,
            665.0
          ],
          "confidence": 0.993236243724823
        },
        {
          "text": "technical information, know-how, documents, materials, software, vectors, constructs, trade secrets, and other valuable business or",
          "bbox": [
            446.0,
            676.0,
            3020.0,
            720.0
          ],
          "confidence": 0.9944519996643066
        },
        {
          "text": "scientific information that iBio will share with CC-Pharming in order to fulfill the purpose of this Agreement, namely, to form a legal",
          "bbox": [
            444.0,
            731.0,
            3021.0,
            777.0
          ],
          "confidence": 0.9856650829315186
        },
        {
          "text": "structure for a collaborative business venture in which CC-Pharming and iBio shall share revenue from product sales. iBio's double-digit",
          "bbox": [
            446.0,
            791.0,
            3021.0,
            833.0
          ],
          "confidence": 0.994662344455719
        },
        {
          "text": "percentage, minority interest in this structure will provide compensation to iBio for providing CC-Pharming with a license to use iBio's.",
          "bbox": [
            444.0,
            844.0,
            3021.0,
            892.0
          ],
          "confidence": 0.9963811039924622
        },
        {
          "text": "Technology and enabling know-how and will provide CC-Pharming with ongoing and mutually agreed technology transfer services",
          "bbox": [
            446.0,
            903.0,
            3021.0,
            945.0
          ],
          "confidence": 0.9966488480567932
        },
        {
          "text": "relevant to the evolving business and Product(s) of the collaborative venture.",
          "bbox": [
            446.0,
            963.0,
            1898.0,
            1000.0
          ],
          "confidence": 0.9989203214645386
        },
        {
          "text": "1.5",
          "bbox": [
            274.0,
            1011.0,
            344.0,
            1058.0
          ],
          "confidence": 0.9999009966850281
        },
        {
          "text": "The parties agree that the first product focus of the joint business collaboration will be a bio-better or bio-similar version of the",
          "bbox": [
            444.0,
            1012.0,
            3020.0,
            1058.0
          ],
          "confidence": 0.996626079082489
        },
        {
          "text": "therapeutic monoclonal antibody, rituximab. iBio will provide all necessary gene expression and vector technology for the transient.",
          "bbox": [
            446.0,
            1073.0,
            3023.0,
            1117.0
          ],
          "confidence": 0.9934687614440918
        },
        {
          "text": "expression and cGMP manufacturing of this protein in plants and will also provide pilot plant design services, construction consulting,",
          "bbox": [
            442.0,
            1124.0,
            3020.0,
            1175.0
          ],
          "confidence": 0.9993672966957092
        },
        {
          "text": "product and process development services, training, quality management system design, and clinical planning and regulatory consulting.",
          "bbox": [
            448.0,
            1186.0,
            3016.0,
            1228.0
          ],
          "confidence": 0.9921608567237854
        },
        {
          "text": "The tasks to be conducted in the first stage of the joint business collaboration will apply specifically to the rituximab product candidate",
          "bbox": [
            442.0,
            1235.0,
            3021.0,
            1286.0
          ],
          "confidence": 0.9976635575294495
        },
        {
          "text": "but will be applicable, in part, to additional products to be selected by mutual agreement for development, with the timeline for such work",
          "bbox": [
            448.0,
            1296.0,
            3021.0,
            1338.0
          ],
          "confidence": 0.9955782294273376
        },
        {
          "text": "to be determined by CC-Pharming.",
          "bbox": [
            444.0,
            1347.0,
            1082.0,
            1398.0
          ],
          "confidence": 0.9862340688705444
        },
        {
          "text": "1.5",
          "bbox": [
            274.0,
            1405.0,
            343.0,
            1449.0
          ],
          "confidence": 0.8620595335960388
        },
        {
          "text": "Any milestones or completion dates set forth in a Statement of Work will be estimates only, and are not binding on the Parties.",
          "bbox": [
            446.0,
            1405.0,
            2789.0,
            1451.0
          ],
          "confidence": 0.995090901851654
        },
        {
          "text": "2.0",
          "bbox": [
            270.0,
            1458.0,
            344.0,
            1508.0
          ],
          "confidence": 0.9997313022613525
        },
        {
          "text": "Coordinators and Governance Terms",
          "bbox": [
            450.0,
            1466.0,
            1144.0,
            1502.0
          ],
          "confidence": 0.9927111268043518
        },
        {
          "text": "2.1",
          "bbox": [
            272.0,
            1517.0,
            343.0,
            1561.0
          ],
          "confidence": 0.998992919921875
        },
        {
          "text": "Project Technical Coordinators will be appointed by each the Parties for each Statement of Work. The Project Technical Coordinators will",
          "bbox": [
            444.0,
            1517.0,
            3020.0,
            1562.0
          ],
          "confidence": 0.9955620765686035
        },
        {
          "text": "be responsible for exchanging information with the other Party, coordinating any visits and arranging all other matters pertinent to that",
          "bbox": [
            446.0,
            1577.0,
            3021.0,
            1619.0
          ],
          "confidence": 0.9937794208526611
        },
        {
          "text": "Statement of Work.",
          "bbox": [
            448.0,
            1634.0,
            803.0,
            1672.0
          ],
          "confidence": 0.9995152354240417
        },
        {
          "text": "Master Joint Development Agreement iBio CC-Pharming",
          "bbox": [
            279.0,
            1741.0,
            1332.0,
            1789.0
          ],
          "confidence": 0.9914409518241882
        },
        {
          "text": "Page 2 of 12",
          "bbox": [
            2800.0,
            1743.0,
            3029.0,
            1787.0
          ],
          "confidence": 0.9996117949485779
        },
        {
          "text": "Source: IBIO, INC., 8-K, 3/13/2020",
          "bbox": [
            335.0,
            4440.0,
            1022.0,
            4477.0
          ],
          "confidence": 0.997024416923523
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "IbioInc_20200313_8-K_EX-10.1_12052678_EX-10.1_Development Agreement__License Grant_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"License Grant\" that should be reviewed by a lawyer. Details: Does the contract contain a license granted by one party to its counterparty?",
      "answer_text": "iBio hereby grants to CC-Pharming for the term of this Agreement, a nonexclusive, non- assignable, non-sublicensable, limited right and license to use iBio's Technology in order to manufacture, process, prepare, and obtain regulatory approval for the development and production of Product(s) and work to be performed under this Agreement.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.1",
          "bbox": [
            2800.0,
            283.0,
            3025.0,
            322.0
          ],
          "confidence": 0.9997009634971619
        },
        {
          "text": "NOTE: Certain information indicated with [***] in this document has been omitted from this exhibit because it is both (i) not material and (ii).",
          "bbox": [
            275.0,
            338.0,
            3027.0,
            384.0
          ],
          "confidence": 0.9894452691078186
        },
        {
          "text": "would be competitively harmful if publicly disclosed.",
          "bbox": [
            281.0,
            397.0,
            1258.0,
            440.0
          ],
          "confidence": 0.9874401688575745
        },
        {
          "text": "MASTER JOINT DEVELOPMENT AGREEMENT",
          "bbox": [
            1182.0,
            455.0,
            2121.0,
            492.0
          ],
          "confidence": 0.9990029335021973
        },
        {
          "text": "This Master Joint Development Agreement (\"Agreement\") is between iBio Inc., a Public corporation, with a location at iBio Inc., 600 Madison Ave,",
          "bbox": [
            275.0,
            504.0,
            3027.0,
            556.0
          ],
          "confidence": 0.9988492131233215
        },
        {
          "text": "Suite O1601 NY, NY 10022-1735 and Beijing CC-Pharming Ltd. of Beijing, China (\"CC-Pharming\"), a Chinese Corporation with a location at Shunyi",
          "bbox": [
            279.0,
            566.0,
            3027.0,
            609.0
          ],
          "confidence": 0.9916648864746094
        },
        {
          "text": "District, Beijing, China, 101312, each of the foregoing being individually referred to as a \"Party\" and collectively as the \"Parties\".",
          "bbox": [
            275.0,
            619.0,
            2664.0,
            665.0
          ],
          "confidence": 0.9942342042922974
        },
        {
          "text": "WHEREAS, iBio and CC-Pharming wish to establish a long-term working relationship for various joint research and development projects",
          "bbox": [
            444.0,
            676.0,
            3027.0,
            724.0
          ],
          "confidence": 0.9975687861442566
        },
        {
          "text": "(\"Projects) related to the development of various products, with the work for each Project to be described in a separate Statement of Work.",
          "bbox": [
            279.0,
            735.0,
            3029.0,
            777.0
          ],
          "confidence": 0.9938633441925049
        },
        {
          "text": "(\"SOw\") agreed by the Parties;",
          "bbox": [
            281.0,
            789.0,
            868.0,
            835.0
          ],
          "confidence": 0.9870513081550598
        },
        {
          "text": "WHEREAS, iBio has developed and owns proprietary technology used to produce proteins using proprietary vector systems that support",
          "bbox": [
            444.0,
            844.0,
            3029.0,
            892.0
          ],
          "confidence": 0.9940124750137329
        },
        {
          "text": "transient gene expression and protein production in plants, and iBio has developed and/or acquired additional proprietary biopharmaceutical",
          "bbox": [
            275.0,
            901.0,
            3031.0,
            947.0
          ],
          "confidence": 0.991813063621521
        },
        {
          "text": "technology, cGMP manufacturing expertise (\"iBio's Technology\"), and a facility design team that provides capabilities for application to the",
          "bbox": [
            279.0,
            963.0,
            3025.0,
            1000.0
          ],
          "confidence": 0.9882965087890625
        },
        {
          "text": "development of biotherapeutics; and.",
          "bbox": [
            279.0,
            1016.0,
            972.0,
            1058.0
          ],
          "confidence": 0.9877834320068359
        },
        {
          "text": "WHEREAs, iBio and CC-Pharming, wish to develop one or more biopharmaceuticals Product(s) (each a \"Product\") based on iBio's",
          "bbox": [
            446.0,
            1071.0,
            3029.0,
            1113.0
          ],
          "confidence": 0.987923264503479
        },
        {
          "text": "proprietary and patented plant-based protein production technology and know-how;.",
          "bbox": [
            275.0,
            1127.0,
            1861.0,
            1173.0
          ],
          "confidence": 0.9903185963630676
        },
        {
          "text": "WHEREAs, iBio and CC-Pharming wish to develop a long-term, mutually beneficial relationship for the production and sale of",
          "bbox": [
            448.0,
            1184.0,
            3030.0,
            1228.0
          ],
          "confidence": 0.9862040281295776
        },
        {
          "text": "biopharmaceuticals in China and to form a collaborative business venture to be majority owned and controlled by CC-Pharming and minority owned",
          "bbox": [
            277.0,
            1237.0,
            3029.0,
            1283.0
          ],
          "confidence": 0.9991291761398315
        },
        {
          "text": "by iBio; and",
          "bbox": [
            279.0,
            1296.0,
            508.0,
            1339.0
          ],
          "confidence": 0.9808014035224915
        },
        {
          "text": "NOw, THEREFORE, for good and valuable consideration as stated herein, the sufficiency of which is hereby expressly acknowledged by",
          "bbox": [
            442.0,
            1349.0,
            3023.0,
            1396.0
          ],
          "confidence": 0.99495530128479
        },
        {
          "text": "each Party, iBio and CC-Pharming agree as follows:",
          "bbox": [
            279.0,
            1409.0,
            1223.0,
            1451.0
          ],
          "confidence": 0.999891996383667
        },
        {
          "text": "1.0",
          "bbox": [
            274.0,
            1460.0,
            344.0,
            1508.0
          ],
          "confidence": 0.9981430172920227
        },
        {
          "text": "Limited Technology License",
          "bbox": [
            446.0,
            1464.0,
            982.0,
            1504.0
          ],
          "confidence": 0.9944542646408081
        },
        {
          "text": "1.1",
          "bbox": [
            274.0,
            1517.0,
            341.0,
            1561.0
          ],
          "confidence": 0.9970695972442627
        },
        {
          "text": "iBio hereby grants to CC-Pharming for the term of this Agreement, a nonexclusive, non- assignable, non-sublicensable, limited right and",
          "bbox": [
            448.0,
            1520.0,
            3021.0,
            1562.0
          ],
          "confidence": 0.996475875377655
        },
        {
          "text": "production of Product(s) and work to be performed under this Agreement. Each Product will be set forth in a separate Statement of Work",
          "bbox": [
            446.0,
            1630.0,
            3021.0,
            1676.0
          ],
          "confidence": 0.9869741201400757
        },
        {
          "text": "in the form set forth in Appendix A, which will be signed by representatives of each Party with signing authority. Each phase of the",
          "bbox": [
            446.0,
            1690.0,
            3020.0,
            1732.0
          ],
          "confidence": 0.9884188175201416
        },
        {
          "text": "project(s) will be subject to the terms and conditions set forth in this Agreement unless otherwise provided for or in a Statement of Work.",
          "bbox": [
            442.0,
            1738.0,
            3023.0,
            1793.0
          ],
          "confidence": 0.9936604499816895
        },
        {
          "text": "(\"SOw'), including but not limited to project purpose, project phases, and a project budget..",
          "bbox": [
            446.0,
            1800.0,
            2159.0,
            1846.0
          ],
          "confidence": 0.9933698773384094
        },
        {
          "text": "Master Joint Development Agreement iBio CC-Pharming",
          "bbox": [
            279.0,
            1910.0,
            1334.0,
            1957.0
          ],
          "confidence": 0.9935949444770813
        },
        {
          "text": "Page 1 of 12",
          "bbox": [
            2800.0,
            1911.0,
            3029.0,
            1955.0
          ],
          "confidence": 0.9980977177619934
        },
        {
          "text": "Source: IBIO, INC., 8-K, 3/13/2020",
          "bbox": [
            333.0,
            4435.0,
            1022.0,
            4479.0
          ],
          "confidence": 0.990613579750061
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "MASTER JOINT DEVELOPMENT AGREEMENT",
          "page": 0,
          "bbox": [
            1182.0,
            455.0,
            2121.0,
            492.0
          ]
        }
      ]
    },
    {
      "id": "IbioInc_20200313_8-K_EX-10.1_12052678_EX-10.1_Development Agreement__License Grant_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"License Grant\" that should be reviewed by a lawyer. Details: Does the contract contain a license granted by one party to its counterparty?",
      "answer_text": "iBio hereby grants to CC-Pharming for the term of this Agreement, a nonexclusive, non- assignable, non-sublicensable, limited right and license to use iBio's Technology in order to manufacture, process, prepare, and obtain regulatory approval for the development and production of Product(s) and work to be performed under this Agreement.",
      "page_number": 1,
      "words": [
        {
          "text": "1.2",
          "bbox": [
            274.0,
            283.0,
            343.0,
            327.0
          ],
          "confidence": 0.999828040599823
        },
        {
          "text": "No right or license is being conveyed to CC-Pharming to export Products or to otherwise use the Technology in any country other than",
          "bbox": [
            444.0,
            283.0,
            3020.0,
            327.0
          ],
          "confidence": 0.9960402250289917
        },
        {
          "text": "China.",
          "bbox": [
            444.0,
            338.0,
            564.0,
            382.0
          ],
          "confidence": 0.9998229146003723
        },
        {
          "text": "1.3",
          "bbox": [
            274.0,
            395.0,
            343.0,
            439.0
          ],
          "confidence": 0.9999030232429504
        },
        {
          "text": "iBio will work with CC-Pharming to perform a thorough Manufacturing Development Program based from an initial comprehensive two-",
          "bbox": [
            444.0,
            395.0,
            3020.0,
            440.0
          ],
          "confidence": 0.991921067237854
        },
        {
          "text": "day charrette to be held at its subsidiary iBio CDMO LLC facility in Bryan, Texas with the goals of CC-Pharming understanding the",
          "bbox": [
            446.0,
            451.0,
            3020.0,
            497.0
          ],
          "confidence": 0.9884581565856934
        },
        {
          "text": "definitive capital expenditure necessary and initiating a preliminary design for the first Product. iBio will provide an architect, construction",
          "bbox": [
            448.0,
            510.0,
            3021.0,
            554.0
          ],
          "confidence": 0.9959992170333862
        },
        {
          "text": "supervisor, mechanical engineer and process engineer with knowledge of the iBio CDMO facility currently in operation in Bryan, Texas.",
          "bbox": [
            448.0,
            566.0,
            2960.0,
            609.0
          ],
          "confidence": 0.9869726896286011
        },
        {
          "text": "1.4",
          "bbox": [
            274.0,
            619.0,
            343.0,
            663.0
          ],
          "confidence": 0.9999340176582336
        },
        {
          "text": "CC-Pharming hereby expressly acknowledges the validity and highly confidential and proprietary nature of iBio's Technology and",
          "bbox": [
            446.0,
            619.0,
            3021.0,
            665.0
          ],
          "confidence": 0.993236243724823
        },
        {
          "text": "technical information, know-how, documents, materials, software, vectors, constructs, trade secrets, and other valuable business or",
          "bbox": [
            446.0,
            676.0,
            3020.0,
            720.0
          ],
          "confidence": 0.9944519996643066
        },
        {
          "text": "scientific information that iBio will share with CC-Pharming in order to fulfill the purpose of this Agreement, namely, to form a legal",
          "bbox": [
            444.0,
            731.0,
            3021.0,
            777.0
          ],
          "confidence": 0.9856650829315186
        },
        {
          "text": "structure for a collaborative business venture in which CC-Pharming and iBio shall share revenue from product sales. iBio's double-digit",
          "bbox": [
            446.0,
            791.0,
            3021.0,
            833.0
          ],
          "confidence": 0.994662344455719
        },
        {
          "text": "percentage, minority interest in this structure will provide compensation to iBio for providing CC-Pharming with a license to use iBio's.",
          "bbox": [
            444.0,
            844.0,
            3021.0,
            892.0
          ],
          "confidence": 0.9963811039924622
        },
        {
          "text": "Technology and enabling know-how and will provide CC-Pharming with ongoing and mutually agreed technology transfer services",
          "bbox": [
            446.0,
            903.0,
            3021.0,
            945.0
          ],
          "confidence": 0.9966488480567932
        },
        {
          "text": "relevant to the evolving business and Product(s) of the collaborative venture.",
          "bbox": [
            446.0,
            963.0,
            1898.0,
            1000.0
          ],
          "confidence": 0.9989203214645386
        },
        {
          "text": "1.5",
          "bbox": [
            274.0,
            1011.0,
            344.0,
            1058.0
          ],
          "confidence": 0.9999009966850281
        },
        {
          "text": "The parties agree that the first product focus of the joint business collaboration will be a bio-better or bio-similar version of the",
          "bbox": [
            444.0,
            1012.0,
            3020.0,
            1058.0
          ],
          "confidence": 0.996626079082489
        },
        {
          "text": "therapeutic monoclonal antibody, rituximab. iBio will provide all necessary gene expression and vector technology for the transient.",
          "bbox": [
            446.0,
            1073.0,
            3023.0,
            1117.0
          ],
          "confidence": 0.9934687614440918
        },
        {
          "text": "expression and cGMP manufacturing of this protein in plants and will also provide pilot plant design services, construction consulting,",
          "bbox": [
            442.0,
            1124.0,
            3020.0,
            1175.0
          ],
          "confidence": 0.9993672966957092
        },
        {
          "text": "product and process development services, training, quality management system design, and clinical planning and regulatory consulting.",
          "bbox": [
            448.0,
            1186.0,
            3016.0,
            1228.0
          ],
          "confidence": 0.9921608567237854
        },
        {
          "text": "The tasks to be conducted in the first stage of the joint business collaboration will apply specifically to the rituximab product candidate",
          "bbox": [
            442.0,
            1235.0,
            3021.0,
            1286.0
          ],
          "confidence": 0.9976635575294495
        },
        {
          "text": "but will be applicable, in part, to additional products to be selected by mutual agreement for development, with the timeline for such work",
          "bbox": [
            448.0,
            1296.0,
            3021.0,
            1338.0
          ],
          "confidence": 0.9955782294273376
        },
        {
          "text": "to be determined by CC-Pharming.",
          "bbox": [
            444.0,
            1347.0,
            1082.0,
            1398.0
          ],
          "confidence": 0.9862340688705444
        },
        {
          "text": "1.5",
          "bbox": [
            274.0,
            1405.0,
            343.0,
            1449.0
          ],
          "confidence": 0.8620595335960388
        },
        {
          "text": "Any milestones or completion dates set forth in a Statement of Work will be estimates only, and are not binding on the Parties.",
          "bbox": [
            446.0,
            1405.0,
            2789.0,
            1451.0
          ],
          "confidence": 0.995090901851654
        },
        {
          "text": "2.0",
          "bbox": [
            270.0,
            1458.0,
            344.0,
            1508.0
          ],
          "confidence": 0.9997313022613525
        },
        {
          "text": "Coordinators and Governance Terms",
          "bbox": [
            450.0,
            1466.0,
            1144.0,
            1502.0
          ],
          "confidence": 0.9927111268043518
        },
        {
          "text": "2.1",
          "bbox": [
            272.0,
            1517.0,
            343.0,
            1561.0
          ],
          "confidence": 0.998992919921875
        },
        {
          "text": "Project Technical Coordinators will be appointed by each the Parties for each Statement of Work. The Project Technical Coordinators will",
          "bbox": [
            444.0,
            1517.0,
            3020.0,
            1562.0
          ],
          "confidence": 0.9955620765686035
        },
        {
          "text": "be responsible for exchanging information with the other Party, coordinating any visits and arranging all other matters pertinent to that",
          "bbox": [
            446.0,
            1577.0,
            3021.0,
            1619.0
          ],
          "confidence": 0.9937794208526611
        },
        {
          "text": "Statement of Work.",
          "bbox": [
            448.0,
            1634.0,
            803.0,
            1672.0
          ],
          "confidence": 0.9995152354240417
        },
        {
          "text": "Master Joint Development Agreement iBio CC-Pharming",
          "bbox": [
            279.0,
            1741.0,
            1332.0,
            1789.0
          ],
          "confidence": 0.9914409518241882
        },
        {
          "text": "Page 2 of 12",
          "bbox": [
            2800.0,
            1743.0,
            3029.0,
            1787.0
          ],
          "confidence": 0.9996117949485779
        },
        {
          "text": "Source: IBIO, INC., 8-K, 3/13/2020",
          "bbox": [
            335.0,
            4440.0,
            1022.0,
            4477.0
          ],
          "confidence": 0.997024416923523
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "IbioInc_20200313_8-K_EX-10.1_12052678_EX-10.1_Development Agreement__Non-Transferable License_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Non-Transferable License\" that should be reviewed by a lawyer. Details: Does the contract limit the ability of a party to transfer the license being granted to a third party?",
      "answer_text": "iBio hereby grants to CC-Pharming for the term of this Agreement, a nonexclusive, non- assignable, non-sublicensable, limited right and license to use iBio's Technology in order to manufacture, process, prepare, and obtain regulatory approval for the development and production of Product(s) and work to be performed under this Agreement.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.1",
          "bbox": [
            2800.0,
            283.0,
            3025.0,
            322.0
          ],
          "confidence": 0.9997009634971619
        },
        {
          "text": "NOTE: Certain information indicated with [***] in this document has been omitted from this exhibit because it is both (i) not material and (ii).",
          "bbox": [
            275.0,
            338.0,
            3027.0,
            384.0
          ],
          "confidence": 0.9894452691078186
        },
        {
          "text": "would be competitively harmful if publicly disclosed.",
          "bbox": [
            281.0,
            397.0,
            1258.0,
            440.0
          ],
          "confidence": 0.9874401688575745
        },
        {
          "text": "MASTER JOINT DEVELOPMENT AGREEMENT",
          "bbox": [
            1182.0,
            455.0,
            2121.0,
            492.0
          ],
          "confidence": 0.9990029335021973
        },
        {
          "text": "This Master Joint Development Agreement (\"Agreement\") is between iBio Inc., a Public corporation, with a location at iBio Inc., 600 Madison Ave,",
          "bbox": [
            275.0,
            504.0,
            3027.0,
            556.0
          ],
          "confidence": 0.9988492131233215
        },
        {
          "text": "Suite O1601 NY, NY 10022-1735 and Beijing CC-Pharming Ltd. of Beijing, China (\"CC-Pharming\"), a Chinese Corporation with a location at Shunyi",
          "bbox": [
            279.0,
            566.0,
            3027.0,
            609.0
          ],
          "confidence": 0.9916648864746094
        },
        {
          "text": "District, Beijing, China, 101312, each of the foregoing being individually referred to as a \"Party\" and collectively as the \"Parties\".",
          "bbox": [
            275.0,
            619.0,
            2664.0,
            665.0
          ],
          "confidence": 0.9942342042922974
        },
        {
          "text": "WHEREAS, iBio and CC-Pharming wish to establish a long-term working relationship for various joint research and development projects",
          "bbox": [
            444.0,
            676.0,
            3027.0,
            724.0
          ],
          "confidence": 0.9975687861442566
        },
        {
          "text": "(\"Projects) related to the development of various products, with the work for each Project to be described in a separate Statement of Work.",
          "bbox": [
            279.0,
            735.0,
            3029.0,
            777.0
          ],
          "confidence": 0.9938633441925049
        },
        {
          "text": "(\"SOw\") agreed by the Parties;",
          "bbox": [
            281.0,
            789.0,
            868.0,
            835.0
          ],
          "confidence": 0.9870513081550598
        },
        {
          "text": "WHEREAS, iBio has developed and owns proprietary technology used to produce proteins using proprietary vector systems that support",
          "bbox": [
            444.0,
            844.0,
            3029.0,
            892.0
          ],
          "confidence": 0.9940124750137329
        },
        {
          "text": "transient gene expression and protein production in plants, and iBio has developed and/or acquired additional proprietary biopharmaceutical",
          "bbox": [
            275.0,
            901.0,
            3031.0,
            947.0
          ],
          "confidence": 0.991813063621521
        },
        {
          "text": "technology, cGMP manufacturing expertise (\"iBio's Technology\"), and a facility design team that provides capabilities for application to the",
          "bbox": [
            279.0,
            963.0,
            3025.0,
            1000.0
          ],
          "confidence": 0.9882965087890625
        },
        {
          "text": "development of biotherapeutics; and.",
          "bbox": [
            279.0,
            1016.0,
            972.0,
            1058.0
          ],
          "confidence": 0.9877834320068359
        },
        {
          "text": "WHEREAs, iBio and CC-Pharming, wish to develop one or more biopharmaceuticals Product(s) (each a \"Product\") based on iBio's",
          "bbox": [
            446.0,
            1071.0,
            3029.0,
            1113.0
          ],
          "confidence": 0.987923264503479
        },
        {
          "text": "proprietary and patented plant-based protein production technology and know-how;.",
          "bbox": [
            275.0,
            1127.0,
            1861.0,
            1173.0
          ],
          "confidence": 0.9903185963630676
        },
        {
          "text": "WHEREAs, iBio and CC-Pharming wish to develop a long-term, mutually beneficial relationship for the production and sale of",
          "bbox": [
            448.0,
            1184.0,
            3030.0,
            1228.0
          ],
          "confidence": 0.9862040281295776
        },
        {
          "text": "biopharmaceuticals in China and to form a collaborative business venture to be majority owned and controlled by CC-Pharming and minority owned",
          "bbox": [
            277.0,
            1237.0,
            3029.0,
            1283.0
          ],
          "confidence": 0.9991291761398315
        },
        {
          "text": "by iBio; and",
          "bbox": [
            279.0,
            1296.0,
            508.0,
            1339.0
          ],
          "confidence": 0.9808014035224915
        },
        {
          "text": "NOw, THEREFORE, for good and valuable consideration as stated herein, the sufficiency of which is hereby expressly acknowledged by",
          "bbox": [
            442.0,
            1349.0,
            3023.0,
            1396.0
          ],
          "confidence": 0.99495530128479
        },
        {
          "text": "each Party, iBio and CC-Pharming agree as follows:",
          "bbox": [
            279.0,
            1409.0,
            1223.0,
            1451.0
          ],
          "confidence": 0.999891996383667
        },
        {
          "text": "1.0",
          "bbox": [
            274.0,
            1460.0,
            344.0,
            1508.0
          ],
          "confidence": 0.9981430172920227
        },
        {
          "text": "Limited Technology License",
          "bbox": [
            446.0,
            1464.0,
            982.0,
            1504.0
          ],
          "confidence": 0.9944542646408081
        },
        {
          "text": "1.1",
          "bbox": [
            274.0,
            1517.0,
            341.0,
            1561.0
          ],
          "confidence": 0.9970695972442627
        },
        {
          "text": "iBio hereby grants to CC-Pharming for the term of this Agreement, a nonexclusive, non- assignable, non-sublicensable, limited right and",
          "bbox": [
            448.0,
            1520.0,
            3021.0,
            1562.0
          ],
          "confidence": 0.996475875377655
        },
        {
          "text": "production of Product(s) and work to be performed under this Agreement. Each Product will be set forth in a separate Statement of Work",
          "bbox": [
            446.0,
            1630.0,
            3021.0,
            1676.0
          ],
          "confidence": 0.9869741201400757
        },
        {
          "text": "in the form set forth in Appendix A, which will be signed by representatives of each Party with signing authority. Each phase of the",
          "bbox": [
            446.0,
            1690.0,
            3020.0,
            1732.0
          ],
          "confidence": 0.9884188175201416
        },
        {
          "text": "project(s) will be subject to the terms and conditions set forth in this Agreement unless otherwise provided for or in a Statement of Work.",
          "bbox": [
            442.0,
            1738.0,
            3023.0,
            1793.0
          ],
          "confidence": 0.9936604499816895
        },
        {
          "text": "(\"SOw'), including but not limited to project purpose, project phases, and a project budget..",
          "bbox": [
            446.0,
            1800.0,
            2159.0,
            1846.0
          ],
          "confidence": 0.9933698773384094
        },
        {
          "text": "Master Joint Development Agreement iBio CC-Pharming",
          "bbox": [
            279.0,
            1910.0,
            1334.0,
            1957.0
          ],
          "confidence": 0.9935949444770813
        },
        {
          "text": "Page 1 of 12",
          "bbox": [
            2800.0,
            1911.0,
            3029.0,
            1955.0
          ],
          "confidence": 0.9980977177619934
        },
        {
          "text": "Source: IBIO, INC., 8-K, 3/13/2020",
          "bbox": [
            333.0,
            4435.0,
            1022.0,
            4479.0
          ],
          "confidence": 0.990613579750061
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "MASTER JOINT DEVELOPMENT AGREEMENT",
          "page": 0,
          "bbox": [
            1182.0,
            455.0,
            2121.0,
            492.0
          ]
        }
      ]
    },
    {
      "id": "IbioInc_20200313_8-K_EX-10.1_12052678_EX-10.1_Development Agreement__Non-Transferable License_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Non-Transferable License\" that should be reviewed by a lawyer. Details: Does the contract limit the ability of a party to transfer the license being granted to a third party?",
      "answer_text": "iBio hereby grants to CC-Pharming for the term of this Agreement, a nonexclusive, non- assignable, non-sublicensable, limited right and license to use iBio's Technology in order to manufacture, process, prepare, and obtain regulatory approval for the development and production of Product(s) and work to be performed under this Agreement.",
      "page_number": 1,
      "words": [
        {
          "text": "1.2",
          "bbox": [
            274.0,
            283.0,
            343.0,
            327.0
          ],
          "confidence": 0.999828040599823
        },
        {
          "text": "No right or license is being conveyed to CC-Pharming to export Products or to otherwise use the Technology in any country other than",
          "bbox": [
            444.0,
            283.0,
            3020.0,
            327.0
          ],
          "confidence": 0.9960402250289917
        },
        {
          "text": "China.",
          "bbox": [
            444.0,
            338.0,
            564.0,
            382.0
          ],
          "confidence": 0.9998229146003723
        },
        {
          "text": "1.3",
          "bbox": [
            274.0,
            395.0,
            343.0,
            439.0
          ],
          "confidence": 0.9999030232429504
        },
        {
          "text": "iBio will work with CC-Pharming to perform a thorough Manufacturing Development Program based from an initial comprehensive two-",
          "bbox": [
            444.0,
            395.0,
            3020.0,
            440.0
          ],
          "confidence": 0.991921067237854
        },
        {
          "text": "day charrette to be held at its subsidiary iBio CDMO LLC facility in Bryan, Texas with the goals of CC-Pharming understanding the",
          "bbox": [
            446.0,
            451.0,
            3020.0,
            497.0
          ],
          "confidence": 0.9884581565856934
        },
        {
          "text": "definitive capital expenditure necessary and initiating a preliminary design for the first Product. iBio will provide an architect, construction",
          "bbox": [
            448.0,
            510.0,
            3021.0,
            554.0
          ],
          "confidence": 0.9959992170333862
        },
        {
          "text": "supervisor, mechanical engineer and process engineer with knowledge of the iBio CDMO facility currently in operation in Bryan, Texas.",
          "bbox": [
            448.0,
            566.0,
            2960.0,
            609.0
          ],
          "confidence": 0.9869726896286011
        },
        {
          "text": "1.4",
          "bbox": [
            274.0,
            619.0,
            343.0,
            663.0
          ],
          "confidence": 0.9999340176582336
        },
        {
          "text": "CC-Pharming hereby expressly acknowledges the validity and highly confidential and proprietary nature of iBio's Technology and",
          "bbox": [
            446.0,
            619.0,
            3021.0,
            665.0
          ],
          "confidence": 0.993236243724823
        },
        {
          "text": "technical information, know-how, documents, materials, software, vectors, constructs, trade secrets, and other valuable business or",
          "bbox": [
            446.0,
            676.0,
            3020.0,
            720.0
          ],
          "confidence": 0.9944519996643066
        },
        {
          "text": "scientific information that iBio will share with CC-Pharming in order to fulfill the purpose of this Agreement, namely, to form a legal",
          "bbox": [
            444.0,
            731.0,
            3021.0,
            777.0
          ],
          "confidence": 0.9856650829315186
        },
        {
          "text": "structure for a collaborative business venture in which CC-Pharming and iBio shall share revenue from product sales. iBio's double-digit",
          "bbox": [
            446.0,
            791.0,
            3021.0,
            833.0
          ],
          "confidence": 0.994662344455719
        },
        {
          "text": "percentage, minority interest in this structure will provide compensation to iBio for providing CC-Pharming with a license to use iBio's.",
          "bbox": [
            444.0,
            844.0,
            3021.0,
            892.0
          ],
          "confidence": 0.9963811039924622
        },
        {
          "text": "Technology and enabling know-how and will provide CC-Pharming with ongoing and mutually agreed technology transfer services",
          "bbox": [
            446.0,
            903.0,
            3021.0,
            945.0
          ],
          "confidence": 0.9966488480567932
        },
        {
          "text": "relevant to the evolving business and Product(s) of the collaborative venture.",
          "bbox": [
            446.0,
            963.0,
            1898.0,
            1000.0
          ],
          "confidence": 0.9989203214645386
        },
        {
          "text": "1.5",
          "bbox": [
            274.0,
            1011.0,
            344.0,
            1058.0
          ],
          "confidence": 0.9999009966850281
        },
        {
          "text": "The parties agree that the first product focus of the joint business collaboration will be a bio-better or bio-similar version of the",
          "bbox": [
            444.0,
            1012.0,
            3020.0,
            1058.0
          ],
          "confidence": 0.996626079082489
        },
        {
          "text": "therapeutic monoclonal antibody, rituximab. iBio will provide all necessary gene expression and vector technology for the transient.",
          "bbox": [
            446.0,
            1073.0,
            3023.0,
            1117.0
          ],
          "confidence": 0.9934687614440918
        },
        {
          "text": "expression and cGMP manufacturing of this protein in plants and will also provide pilot plant design services, construction consulting,",
          "bbox": [
            442.0,
            1124.0,
            3020.0,
            1175.0
          ],
          "confidence": 0.9993672966957092
        },
        {
          "text": "product and process development services, training, quality management system design, and clinical planning and regulatory consulting.",
          "bbox": [
            448.0,
            1186.0,
            3016.0,
            1228.0
          ],
          "confidence": 0.9921608567237854
        },
        {
          "text": "The tasks to be conducted in the first stage of the joint business collaboration will apply specifically to the rituximab product candidate",
          "bbox": [
            442.0,
            1235.0,
            3021.0,
            1286.0
          ],
          "confidence": 0.9976635575294495
        },
        {
          "text": "but will be applicable, in part, to additional products to be selected by mutual agreement for development, with the timeline for such work",
          "bbox": [
            448.0,
            1296.0,
            3021.0,
            1338.0
          ],
          "confidence": 0.9955782294273376
        },
        {
          "text": "to be determined by CC-Pharming.",
          "bbox": [
            444.0,
            1347.0,
            1082.0,
            1398.0
          ],
          "confidence": 0.9862340688705444
        },
        {
          "text": "1.5",
          "bbox": [
            274.0,
            1405.0,
            343.0,
            1449.0
          ],
          "confidence": 0.8620595335960388
        },
        {
          "text": "Any milestones or completion dates set forth in a Statement of Work will be estimates only, and are not binding on the Parties.",
          "bbox": [
            446.0,
            1405.0,
            2789.0,
            1451.0
          ],
          "confidence": 0.995090901851654
        },
        {
          "text": "2.0",
          "bbox": [
            270.0,
            1458.0,
            344.0,
            1508.0
          ],
          "confidence": 0.9997313022613525
        },
        {
          "text": "Coordinators and Governance Terms",
          "bbox": [
            450.0,
            1466.0,
            1144.0,
            1502.0
          ],
          "confidence": 0.9927111268043518
        },
        {
          "text": "2.1",
          "bbox": [
            272.0,
            1517.0,
            343.0,
            1561.0
          ],
          "confidence": 0.998992919921875
        },
        {
          "text": "Project Technical Coordinators will be appointed by each the Parties for each Statement of Work. The Project Technical Coordinators will",
          "bbox": [
            444.0,
            1517.0,
            3020.0,
            1562.0
          ],
          "confidence": 0.9955620765686035
        },
        {
          "text": "be responsible for exchanging information with the other Party, coordinating any visits and arranging all other matters pertinent to that",
          "bbox": [
            446.0,
            1577.0,
            3021.0,
            1619.0
          ],
          "confidence": 0.9937794208526611
        },
        {
          "text": "Statement of Work.",
          "bbox": [
            448.0,
            1634.0,
            803.0,
            1672.0
          ],
          "confidence": 0.9995152354240417
        },
        {
          "text": "Master Joint Development Agreement iBio CC-Pharming",
          "bbox": [
            279.0,
            1741.0,
            1332.0,
            1789.0
          ],
          "confidence": 0.9914409518241882
        },
        {
          "text": "Page 2 of 12",
          "bbox": [
            2800.0,
            1743.0,
            3029.0,
            1787.0
          ],
          "confidence": 0.9996117949485779
        },
        {
          "text": "Source: IBIO, INC., 8-K, 3/13/2020",
          "bbox": [
            335.0,
            4440.0,
            1022.0,
            4477.0
          ],
          "confidence": 0.997024416923523
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "IbioInc_20200313_8-K_EX-10.1_12052678_EX-10.1_Development Agreement__Uncapped Liability_7_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Uncapped Liability\" that should be reviewed by a lawyer. Details: Is a party’s liability uncapped upon the breach of its obligation in the contract? This also includes uncap liability for a particular type of breach such as IP infringement or breach of confidentiality obligation.",
      "answer_text": "Except for claims arising out of Articles 4.3 and 7.0, or as may be set forth in a SOW, neither Party will be liable for any consequential damages, lost profits, lost savings, loss of anticipated revenue, or any exemplary, punitive, special or indirect damages, even if advised of their possibility.",
      "page_number": 7,
      "words": [
        {
          "text": "Except for claims arising out of Articles 4.3 and 7.0, or as may be set forth in a SOw, neither Party will be liable for any consequential",
          "bbox": [
            448.0,
            285.0,
            3020.0,
            327.0
          ],
          "confidence": 0.99208003282547
        },
        {
          "text": "damages, lost profits, lost savings, loss of anticipated revenue, or any exemplary, punitive, special or indirect damages, even if advised of",
          "bbox": [
            446.0,
            340.0,
            3027.0,
            386.0
          ],
          "confidence": 0.9953416585922241
        },
        {
          "text": "their possibility.",
          "bbox": [
            446.0,
            398.0,
            741.0,
            442.0
          ],
          "confidence": 0.9997237324714661
        }
      ],
      "multi_page": true,
      "part_of": 1
    },
    {
      "id": "IbioInc_20200313_8-K_EX-10.1_12052678_EX-10.1_Development Agreement__Cap On Liability_7_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Cap On Liability\" that should be reviewed by a lawyer. Details: Does the contract include a cap on liability upon the breach of a party’s obligation? This includes time limitation for the counterparty to bring claims or maximum amount for recovery.",
      "answer_text": "Except for claims arising out of Articles 4.3 and 7.0, or as may be set forth in a SOW, neither Party will be liable for any consequential damages, lost profits, lost savings, loss of anticipated revenue, or any exemplary, punitive, special or indirect damages, even if advised of their possibility.",
      "page_number": 7,
      "words": [
        {
          "text": "Except for claims arising out of Articles 4.3 and 7.0, or as may be set forth in a SOw, neither Party will be liable for any consequential",
          "bbox": [
            448.0,
            285.0,
            3020.0,
            327.0
          ],
          "confidence": 0.99208003282547
        },
        {
          "text": "damages, lost profits, lost savings, loss of anticipated revenue, or any exemplary, punitive, special or indirect damages, even if advised of",
          "bbox": [
            446.0,
            340.0,
            3027.0,
            386.0
          ],
          "confidence": 0.9953416585922241
        },
        {
          "text": "their possibility.",
          "bbox": [
            446.0,
            398.0,
            741.0,
            442.0
          ],
          "confidence": 0.9997237324714661
        }
      ],
      "multi_page": true,
      "part_of": 1
    }
  ]
}